NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34201]  
Morrisville, NC [ZIP_CODE]  
  

NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 2 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   CONFIDENTIALITY STATEMENT  
The information contained in this protocol and all other information relevant to SB206 are the 
confidential and proprietary information of Novan , and except as may be required by [CONTACT_1032], 
state, or local laws or regulation, may not be disclosed to others without prior written permission of Novan. 
STATEMENT OF COMPLIANCE  
The study will be conducted in compliance with this clinical study protocol, Good Clinical Practices (GCP) as outlined by [CONTACT_12212] E6(R2), and all applicable local and national regulatory requirements. Enrollment at any clinical study site may not begin prior to that site receiving approval from the ethics committee of record for the protocol and all materials provided to potential participants.  
Any amendments to the protocol or changes to the consent document will be approved before implementation of that amendment. Reconsent of previously enrolled participants may be necessary depending on the nature of the amendment. 
The Principal Investigator [INVESTIGATOR_34592] t o the study plan as defined by [CONTACT_34635], unless such a change is necessary to eliminate an immediate hazard to the study participants. 
All personnel involved in the conduct of this study have completed Human Subjects Protection 
and GCP Training as outlined by [CONTACT_34636]. 
 
 
 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 3 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   SPONSOR’S APPROVAL  
Title  A Phase 3 Multi -Center, Randomized, Double -Blind, Vehicle- Controlled, Parallel 
Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily 
in the Treatment of Molluscum Contagiosum  
Protocol Number  NI-MC304  
Version Number  3.0 
Version Date 30 Sep 2020  
Amendment  2 
The design of this study as outlined by [CONTACT_34637]’s responsible personnel as indicated in the signature [CONTACT_34702]. 
 
Medical Representative 
Name:  [CONTACT_1641]:  Signature:  [CONTACT_1782]:  
Tomoko Maeda- Chubachi  Vice President, Medical    
Regulatory Representative  
Name:  [CONTACT_1641]:  Signature:  [CONTACT_1782]:  
Emily de León Senior Director of 
Regulatory Operations    
Biostatistics Representative  
Name:  [CONTACT_1641]:  Signature:  [CONTACT_1782]:  
David Hebert  Senior Director, Head of 
Biometrics    
  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 4 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   INVESTIGATOR’S AGREEMENT  
I have read the protocol, appendices, and accessory materials related to Study NI -MC304 and 
agree to the following: 
• To conduct this study as described by [CONTACT_34638] 
• To protect the rights, safety, and welfare of the participants under my care 
• To provide oversight to all personnel to whom study activities have been delegated 
• To control all investigational products provided by [CONTACT_34639] 
• To conduct the study in accordance with all applicable local and national regulations, the 
requirements of the ethics committee of record for my clinical site, and Good Clinical 
Practices as outlined by [CONTACT_12212] E6(R2). 
• To obtain approva l for the protocol and all written materials provided to participants prior 
to initiating the study at my site  
• To obtain informed consent – and updated consent in the event of new information or 
amendments – from all participants enrolled at my study site prior to initiating any study-
specific procedures or administering investigational products to those participants 
• To maintain records of each subject’s participation and all data required by [CONTACT_34640]-MC304 Clinical Study Protocol Confidential 
SB206 Page 5 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   SUMMARY OF CHANGES  
The major changes incorporated into this protocol (Version 3.0) relative to the prior approved 
version (Version 2.0) are summarized in the table below. 
Section 
Number  Section Title  Summary of Change  Rationale for Change  
10.2.[ADDRESS_34202] treatment difference   
Multiple 
sections  Changed throughout protocol for 
consistency  Permit remote or in -clinic visit to be 
performe d at Visit 4/Week 4, and in -clinic 
visit to be performed at V5/Week 8  Ensuring data quality and 
operational ease for 
subjects/caregivers  
 
 
  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 6 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   TABLE OF CONTENTS  
CONFIDENTIALITY STATEMENT  ........................................................................................... 2  
STATEMENT OF COMPLIANCE  ............................................................................................... 2  
SPONSOR’S APPROVAL  ............................................................................................................ 3  
INVESTIGATOR’S AGREEMENT  ............................................................................................. [ADDRESS_34203] OF ABBREVIATIONS  ...................................................................................................... 12  
1 SYNOPSIS  ....................................................................................................................... 14  
1.1 Study Schematic............................................................................................................ 19  
1.2 Schedule of Assessments  .............................................................................................. 20  
2 INTRODUCTION  ........................................................................................................... 23  
2.1 Background ................................................................................................................... 23  
2.1.1  Target Indication and Population ............................................................................... 24  
2.1.2  Description of SB206 ................................................................................................. 24  
[IP_ADDRESS]  Administration Regimen  ......................................................................................... 24  
[IP_ADDRESS]  Justification for Dosing Strategy ............................................................................ 25  
2.1.3  Supportive Nonclinical Data ...................................................................................... 25  
2.1.4  Supportive Clinical Data  ............................................................................................ 25  
[IP_ADDRESS]  Clinical Pharmacology and Pharmacokinetics........................................................ 25  
[IP_ADDRESS]  Clinical Safety  ......................................................................................................... 27  
[IP_ADDRESS]  Clinical Efficacy  ..................................................................................................... 28  
2.1.5  Benefit: Risk Assessment  .......................................................................................... 30  
2.2 Study Rationale ............................................................................................................. 30  
3 OBJECTIVES AND ENDPOINTS  ................................................................................. 31  
4 STUDY PLAN  ................................................................................................................. 32  
4.1 Study Design ................................................................................................................. 32  
4.2 Number of Participants and Study Sites ....................................................................... 35  
4.3 Treatment Arms and Duration  ...................................................................................... 35  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 7 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   5 POPULATION  ................................................................................................................ 35  
5.1 Eligibility Criteria and Definitions  ............................................................................... 35  
5.2 Inclusion Criteria  .......................................................................................................... 36  
5.3 Exclusion Criteria  ......................................................................................................... 36  
5.4 Subjec t Screening .......................................................................................................... 37  
5.5 Screen Failures  .............................................................................................................. 38  
5.6 Deviation from Inclusion/Exclusion Criteria  ................................................................ [ADDRESS_34204] Engagement and Retention .............................................................................. 39  
6.3 Study Visit Scheduling ................................................................................................. 39  
6.4 Remote Visits  ................................................................................................................ 39  
6.5 Unscheduled Visits ....................................................................................................... 40  
6.6 Order of Assessments  ................................................................................................... 40  
6.7 Study Procedures by [CONTACT_24326]................................................................................... 40  
6.7.1  Screening (Day –15 to Day 1) (In- Clinic Visit) ......................................................... 40  
6.7.2  Visit 1/Baseline (Day 1) (In -Clinic Visit)  .................................................................. 41  
6.7.3  Visit 2/Day 2 (Telephone Contact) ............................................................................ 42  
6.7.4  Visit 3/Week 2 (Day 15 ± 3 days) (In- clinic Visit)  ................................................... 42  
6.7.5  Visit 4/Week 4 (Day 29 ± 5 days) (In- clinic or Remote Visit)  .................................. 42  
6.7.6  Visit 5/Week 8 (Day 57 ± 5 days) (In- clinic Visit)  ................................................... 43  
6.7.7  Visit 6/Week 12/ET (Day 85 ±5 days) (In- clinic Visit)  ............................................ 43  
6.7.8  Visit 7/Week 16 and Visit 8/Week 20 (Day 113 ±7 days; Day 141 ±7 days) 
(Telephone Contact)................................................................................................... 44  
6.7.9  Visit 9/Week 24 (Day 169 ± 7 days) (In- clinic Visit)  ............................................... 44  
6.8 Discontinuation or Withdrawal ..................................................................................... 45  
6.8.1  Individual Subjects..................................................................................................... 45  
6.8.2  Treatment Modifications, Interruptions, and Discontinuation ................................... 45  
[IP_ADDRESS]  Temporary Treatment Discontinuation ................................................................... 46  
[IP_ADDRESS]  Permanent Discontinuation of Treatment ............................................................... [ADDRESS_34205] to Follow-up ........................................................................................ 47  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 8 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   6.9 Study Termination ........................................................................................................ 48  
7 DESCRIPTION OF STUDY ASSESSMENTS  .............................................................. 48  
7.1 Efficacy  Assessments .................................................................................................... 48  
7.1.1  Molluscum Contagiosum Lesion Counts ................................................................... 48  
7.1.2  Other Assessments  ..................................................................................................... 49  
[IP_ADDRESS]  BOTE Inflammation Score  ..................................................................................... 49  
[IP_ADDRESS]  Investigator Global Severity Assessment ............................................................... 50  
[IP_ADDRESS]  Subject Global Severity Assessment  ...................................................................... 50  
[IP_ADDRESS]  Investigator Global Impression of Change ............................................................. 51  
[IP_ADDRESS]  Subject Global Impression of Change .................................................................... 51  
[IP_ADDRESS]  Study Exit Interview ............................................................................................... 51  
7.2 Safety Assessments  ....................................................................................................... 51  
7.2.1  Physical Exam  ............................................................................................................ 51  
7.2.2  Pregnancy Testing ...................................................................................................... 52  
7.2.3  Local Skin Reaction Assessment  ............................................................................... 52  
7.2.4  Scarring/Keloid Assessment  ...................................................................................... [ADDRESS_34206] Dermatitis and Patch Testing  .................................... 54  
7.2.6  Adverse Events  .......................................................................................................... 54  
8 STUDY DRUG TREATMENT  ....................................................................................... 54  
8.1 Description of Products................................................................................................. 54  
8.1.1  Formulation, Storage, Preparation, and Handling ..................................................... 55  
8.2 Dosing and Administration ........................................................................................... 56  
8.3 Treatment Allocation  .................................................................................................... 57  
8.4 Randomization Strategy and Procedure ........................................................................ 57  
8.5 Extent and Maintenance of Blinding ............................................................................ 57  
8.5.1  Unblinding Procedures............................................................................................... 57  
[IP_ADDRESS]  Planned Unblinding ................................................................................................ 57  
[IP_ADDRESS]  Unplanned or Unintentional Unblinding ................................................................ 58  
8.6 Assessment and Verification of Compliance ................................................................ 58  
8.7 Prior and Concomitant Therapi[INVESTIGATOR_014] ................................................................................. 58  
8.7.1  Prohibited Therapi[INVESTIGATOR_014] .................................................................................................. 59  
9 SAFETY MONITORING ................................................................................................ 59  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 9 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   9.1 Definitions ..................................................................................................................... 59  
9.2 Documenting Adverse Events....................................................................................... 60  
9.2.1  Assessment of Severity  .............................................................................................. 61  
9.2.2  Assessment of Causality  ............................................................................................ 61  
9.2.3  Reporting Serious Adverse Events ............................................................................ 61  
9.3 Adverse Event Follow- up ............................................................................................. 62  
9.4 Women of Childbearing Potential & Pregnancy .......................................................... 63  
9.5 Overdose or Misuse ...................................................................................................... 64  
10 ANALYSIS  ...................................................................................................................... 64  
10.1  Hypothesis..................................................................................................................... 64  
10.2  Population ..................................................................................................................... 64  
10.2.1  Sample Size Rationale ............................................................................................... 64  
10.2.2  Analysis Subsets ........................................................................................................ 65  
10.2.3  General Considerations .............................................................................................. 65  
10.3  Testing Procedures ........................................................................................................ 66  
10.3.1  Analysis of the Primary Efficacy Endpoint ............................................................... 66  
10.3.2  Analysis of Secondary Efficacy Endpoints................................................................ 66  
10.3.3  Population Analysis ................................................................................................... 67  
[IP_ADDRESS]  Disposition .............................................................................................................. 67  
[IP_ADDRESS]  Demographics and Baseline Characteristics  ........................................................... 67  
10.3.4  Safety Analysis  .......................................................................................................... 67  
[IP_ADDRESS]  Adverse Events  ....................................................................................................... 67  
[IP_ADDRESS]  Local Skin Reactions  .............................................................................................. [ADDRESS_34207] (DSMB) ....................................................................... 69  
11.3  Ethics Review  ............................................................................................................... 69  
11.4  Informed Consent.......................................................................................................... 69  
11.5  Data Privacy  .................................................................................................................. 70  
11.6  Disclosure ..................................................................................................................... 70  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 10 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   12 OVERSIGHT  ................................................................................................................... 70  
12.1  Quality Control and Assurance ..................................................................................... 70  
12.1.1  Monitoring ................................................................................................................. 70  
12.1.2  Audits ......................................................................................................................... 72  
12.1.3  Protocol Modification/Deviations .............................................................................. 72  
12.1.4  Records  ...................................................................................................................... 72  
[IP_ADDRESS]  Data Capture and Management  ............................................................................... 72  
[IP_ADDRESS]  Source Documentation ............................................................................................ 73  
[IP_ADDRESS]  Study Files and Records Retention ......................................................................... [ADDRESS_34208] OF TABLES  
Table 1  Schedule of Assessments  ..................................................................................... 21  
Table 2  Overall Summary of TEAEs (Safety Population) through Week 24 ................... 27  
Table 3  TEAEs in ≥ 2% of subjects in either SB206 treated group or Vehicle group (NI -
MC301) ................................................................................................................ 27  
Table 4  TEAEs in ≥ 2% of subjects in either SB206 treated group or Vehicle group (NI -
MC302) ................................................................................................................ [ADDRESS_34209] Reactions (at each time point)  ........................... 77  
Table 10  Challenge Reaction Interpretation (based on the last reading (at least 48 hours 
after patch removal)  ............................................................................................. [ADDRESS_34210] OF FIGURES  
Figure 1  Study Timeline Diagram ...................................................................................... 20  
Figure 2  NI-MC301: Percentage of Subjects with Complete Clearance ............................ 28  
Figure 3  NI-MC302: Percentage of Subjects with Complete Clearance ............................ 29  
Figure 4  Structure of Berdazimer Sodium (active ingredient in SB206) ........................... [ADDRESS_34211]  
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonis ation  
IEC Independent Ethics Committee 
IP Investigational Product 
IRB Institutional Review Board  
ITT Intent -to-Treat  
IUD Intrauterine Device  
IUS Intrauterine Hormone Releasing System 
IWRS  Interactive Web Response System  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 13 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   LLOQ  Lower Limit of Quantitation  
LSR Local skin reaction (post exposure to study drug) 
MC Molluscum Contagiosum  
MedDRA  Medical Dictionary of Regulatory Affairs  
NO Nitric Oxide  
NOVAN  Novan, Inc.  
OTC  Over  the counter  
PK Pharmacokinetic  
PP 
 Per-Protocol Population 
  QD Once daily  
SAE  Serious Adverse Event 
SAF Safety Population  
SAP 
 Statistical Analysis Plan  
   SD Standard Deviation 
SOA Schedule of Assessments  
SOC  System Organ Class  
SOP Standard Operating Procedure  
TEAE Treatment Emergent Adverse Event  
UPT  
 
 Urine Pregnancy Test  
    
     
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 14 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   1 SYNOPSIS  
Title  A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-
Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
 
Short Title  A Phase 3 Molluscum Contagiosum Efficacy and Safety Study  
Acronym  B-SIMPLE4  
Phase  3 
Study Design  This is a phase 3 multi -center, randomized, double -blind, vehicle -
controlled, parallel group study to be conducted in up to 
approximately 850 subjects 6 months of age and older with molluscum contagiosum (MC). After obtaining informed 
consent/assent, subje cts who satisfy entry criteria will be 
randomized 1:1 (active:vehicle). Subjects receiving current 
treatment for MC at the time of the Screening Visit will enter a wash out period of up to 14 days prior to randomization. In the 
event no wash out period is required, Screening and Baseline visit 
activities may be combined into a single visit. At randomization, subjects will be stratified by [CONTACT_34641] (dermatologist vs. other), the subject’s BOTE score at Baseline (no inflammation 
(BOTE = 0) vs. mild/m oderate/severe inflammation (BOTE ≥ 1) 
and number of randomized subjects per household ([ADDRESS_34212] per 
household vs. 2 subjects per household). Subjects will be stratified to [ADDRESS_34213] to investigator type and baseline BOTE score because the overall sample size that is expected for 
the stratum for households with two subjects is not large enough 
to support further stratification. 
The sponsor, investigator, site staff and study subjects will remain blinded to the study treatment during this study. All treatments are dosed topi[INVESTIGATOR_897], once daily (QD). Each dose will consist of berdazimer gel or vehicle gel that will be mixed with hydrogel on 
a supplied dosing guide, and then immediately applied by [CONTACT_34642](s).  
 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34214] to stop treatment. If treatment is stopped due to clearance, subjects will continue regularly scheduled visits through Week 24/ET2. Study drug will be 
dispensed through Week 12/ET1 in case of lesion recurrence 
between study visits. At each visit subsequent to stoppi[INVESTIGATOR_34593], t he investigator will determine if new 
lesions have occurred since the last visit, and if so, the subject or 
caregiver will be instructed by [CONTACT_34643]- initiate 
treatment . If the subject or caregiver see new lesions or re-
occurrence of lesions in between visits, they should treat these 
lesions until the next visit. No study drug is planned to be provided after the Week [ADDRESS_34215] 
2 cm from the edge of the eye.   
Subjects will visit the clinic in person at Screening/Baseline, 
Week 2, Week 4 (unless visit is performed remotely), Week 8, 
Week 12, and Week 24. At Baseline, the i nvestigator will perform 
in person lesion counts. Then, the subjects/caregivers will be 
instructed on how to participate in remote  visits  and practice the 
technology. Once the initial in person lesion count has been completed by [CONTACT_33709], an additional count by [CONTACT_34644] a training for future  remote  visit.  
Subjects will be contact[CONTACT_34645] [ADDRESS_34216] 
information on early dose reactions. The Week 4 Visit may be performed remotely or as an in- clinic visit.  At Weeks 16 and 20, 
subjects will be contact[CONTACT_34646] (AEs); at Week [ADDRESS_34217] will be seen at the site for a final study visit to assess 
scarring , keloids, and MC recurrence. Subjects who discontinue 
the study prior to the Week 12 visit due to AEs  or other reasons 
will be asked to complete the  Week 12 visit assessments; this will 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 16 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   be recorded as an Early Termination (ET 1) visit. Subjects who 
discontinue from the study after Week 12 but prior to Week 24 
will be asked to come to the site to complete Week 24 assessments; this visit will be recorded  as an ET2 visit.  
Safety assessments include Beginning of the End (BOTE) Inflammation Scores, Local Skin Reactions (LSRs), adverse event collection, including presence of scars/keloids, and urine pregnancy tests (UPTs). Safety assessments except UPTs  will be 
completed at all  visits through Week 12; UPTs will be completed 
at Screening , Baseline, and Week 12. After Week 12, safety 
information for ongoing and new AEs will be collected, along with information regarding household MC occurrence. 
Additional procedures include subject/caregiver completion of a  
the Global Severity Assessment and the Global Impression of Change Assessment by [CONTACT_27379]/caregiver at Week [ADDRESS_34218]/caregiver’s experience with MC and 
current MC disease state . A select number of sites will also 
consent subjects/caregivers to participate in a study exit interview, 
to be arranged by a third party after completion of Week 12. The intervi ew will include questions to further detail the 
subject/caregiver perspective of their MC and treatment experience. 
Target Population  Males and females, 6 months  of age and older, with a minimum of 
3 and a maximum of 70 MC lesions at Baseline 
Number of Subjects Approximately 850 
Subjects will be assigned 1:1  to active:vehicle .  
Length of Participation  On treatment: Approximately 12 weeks Safety follow-up period: Approximately 12 weeks  
In study (including screening and safety follow- up): Up to 
approximately 26 weeks  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 17 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Intervention  SB206 10.3% or Vehicle Gel once daily  
Inflammatory reactions around the MC have been associated with 
imminent resolution of MC (sometimes referred to as “beginning-of-the- end” [“BOTE”] sign). In most cases, clinical features can 
differentiate between BOTE and LSR. BOTE may be associated with itch, but not pain. BOTE is usually asymptomatic, self-limited, localized to individual MC lesions, and does not require discontinuation of study treatment or additional treatment. LSR is 
generally more diffuse, associated with significant itch or 
tendernes s, may necessitate discontinuation of study treatment,  
and may need treatment for symptomatic relief (e.g. a topi[INVESTIGATOR_34594]). For very severe LSR, 
systemic corticosteroids may be considered. Investigators will 
assess the treatment area at each scheduled visit and use their medical judgement to differentiate between BOTE and LSRs. The subject’s baseline skin inflammatory condition will be assessed as part of the physical examination to be completed prior to 
randomization. BOTE I nflammation Score and LSR scores will be 
recorded at each visit.  LSRs will be rated on individual features 
including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. When LSRs are 
clinically significant, the  investigator should report the condition 
as AE(s).  
Clinically significant LSRs that are reported as adverse events 
and/or subject reported intolerability (i.e. itching, pain) may result 
in an investigator directed temporary treatment hold (drug 
holiday), and topi[INVESTIGATOR_34595] 2 weeks. Per the investigator’s instructions, the subject  may 
re-initiate study drug treatment prior to the next scheduled visit. 
Upon re-initiation (challenge) of study drug treatment, if a subject develops worsening LSRs, allergic contact [CONTACT_34647]. In the event of suspected allergic contact [CONTACT_8748], photographs may be taken of the affected area(s) and transmitted 
to the contract research organization (CRO) medical monitor for 
review and confirmation of allergic contact [CONTACT_34648]. Consent must  be in place for patch testing 
to occur. The investigator should also discuss the necessity of patch testing with the subject/caregiver. The investigator will then 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34219] from study drug treatment and treat the 
area(s) with corticosteroids for up to [ADDRESS_34220] 
provides consent/assent, the investigator will consult the CRO medical monitor prior to  implementing the process for patch 
testing.  
Adverse events will be assessed and collected after the initiation of study drug treatment through the end of the subject’s last visit. Treatment related adverse events will be followed up until 
resolution or up to one year after last treatment, whichever is 
sooner.  
The investigator will map locations of the molluscum lesions at 
Baseline in clinic and th rough the remote  visit platform . The 
investigator will count and record the number of active (raised, treatable) molluscum lesions per body area. Additional lesions identified through Week 12 will be mapped at each visit. Using the map as a guidance, the i nvestigator will assess the treated 
areas for scar/keloid formation. Scar formation will be assessed 
starting at the Week 4 visit through Week 12 and again at Week 
24. Scars will be considered an adverse event for the purposes of this study. In addition, treatment related keloid/hypertrophic scars will also be recorded as adverse events.  
If a subject’s treatment is discontinued by [CONTACT_34649], that AE should be indicated as the reason for treatment discontinuation. All subjects will be encouraged to remain in the study throughout the 24-week study 
duration, even if treatment is discontinued prematurely. 
Primary Endpoint  This study is being conducted to evaluate the efficacy and safety 
of SB206 10.3% QD for the treatment  of MC. The primary 
endpoint will evaluate the proportion of subjects with complete clearance of all treatable MC at Week 12.  
Secondary Endpoints  • Proportion of subjects achieving a lesion count of 0 or 1  of all 
treatable MC at Week 12  
• Proportion of subjects achieving at least a 90% reduction from Baseline in the number of all treatable MC at Week 12  
• Proportion of subjects with complete clearance of all treatable 
MC at Week 8  
• Percent change from Baseline in the number of all treatable MC 
at Week 4  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 19 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Safety Endpoints  • Incidence of treatment -emergent adverse events  
• Change from Baseline in LSR scores  
• Change from Baseline in abbreviated physical examinations 
• Concomitant medications reported 
• Proportion of subject(s) with reported scar(s) 
Other Endpoint  • Change from Baseline in BOTE scores  
Exploratory Endpoints  • Percent change from Baseline in number of treatable MC at 
Weeks 2, 8, and 12 
• Proportion of subjects achieving a lesion count of 0 or 1 of all 
treatable MC at Week s 2, 4, and 8 
• Proportion of subjects achieving at least a 90 % reduction from 
Baseline in the number of all treatable MC at  Week s 2, 4 and 8 
• Proportion of subjects achieving at least a 75% reduction from 
Baseline in the number of all treatable MC at  Week s 2, 4, 8 and 
12 
• Absolute change from Baseline in number of treatable MC at 
Weeks 2, 4, 8 and 12 
• Proportion of subjects with complete clearance of all treatable 
MC at Weeks 2  and 4 
• Time to complete clearance of all treatable MC  
• Proportion of subjects who have a recurrence of MC after the first visit at which complete clearance was observed  
• Subject -reported spread to household members as measured by 
[CONTACT_34650] 2, 4, 8, 12 
• Investigator Global Severity Assessment at Baseline, Week 12 
and 24 
• Subject Global Severity Assessment at Baseline, Week 12 and 
24 
• Investigator Global Impression of Change at Week 12 and 24 
• Subject Global Impression of Change at Week 12 and 24 
Number of Sites Approximately 55 sites in the [LOCATION_002]  
Study Duration Estimated start date: 01 Sep 2020  
Projected stop date: 31 Mar 2021  
Estimated duration: 3.5 months of enrollment 
1.1 Study Schematic  
The study schematic is presented in Figure 1.
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 20 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   
Visit 5 
 
Day 57±5  Visit 6/ET 1  
 
Day 85±5  Visit 7 
 
Day 113±7 Visit 8 
 
Day 141±7 Visit 9/ET2  
 
Day 169±7 
Visit 4  
 
Day 29±5  
Figure 1 Study Timeline Diagram  
           
  SB206 (berdazimer) gel 10.3% QD  
No treatment after  Week 12  through 24   
  Vehicle gel   
   
 Screening  
Up to 2 
weeks  Randomized Treatment Period (Double -Blind)  
12 weeks  Safety Follow -Up Period (Double -Blind)  
12 weeks   
           
           
                                 
           
*Subjects that do not  require a washout may have Screening and Baseline procedures conducting on the same day. Screening/Baseline visits will be do ne in -
clinic  if completed on the same day.  
*Week 12 procedures should be completed for subjects who early terminate (ET) from the study  prior to Week 12; Week 24 procedures should be completed 
for subjects who ET after Week 12 but prior to Week 24 .  
 
1.2 Schedule of Assessments 
The schedule of assessments (SO A) is presented in  Table 1. 
  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 21 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Table 1 Schedule of Assessments  
 Screening  Treatment  
 Screening1 
(Day -15 to 
Day 1)  Visit 11 
Baseline 
(Day 1)  Visit 2  
TC 
(Day 2)  Visit 32 
Week 2  
(Day 15 ±3)  Visit 42 
Week 4  
(Day 29 ±5)  Visit 52 
Week 8  
(Day 57 ±5)  Visit 62 
Week 12/ ET 1 
(Day 85 ±5)  
Informed Consent (Assent)  X       
Demographics  X       
Medical and Medication History  X       
Molluscum Lesion Count  X X3  X X X X 
Physical Exam4  X     X 
Urine Pregnancy Test5 X6 X     X 
BOTE Inflammation Score7  X 
(pre-dose)   X X X X 
Local Skin Reactions (LSR)8  X 
(post -dose)   X X X X 
Scarring/Keloid Assessment      X X X 
Review of Inclusion/Exclusion Criteria  X X      
Drug Dispensed   X   X X  
Collect Study Drug      X X X 
Provide instructions on and test remote visit technology   X      
Provide Subject Diary   X      
Review Subject Application Instructions   X  X X X  
In Clinic Study Drug Application9  X  X X X X 
Review/reinforce Study Drug Compliance    X X X X 
Record Adverse Event (AE) and Concomitant Medication 
(CM) Changes   X X X X X X 
Household status of MC10 X X  X X X X 
Investigator Global Severity Assessment & Subject Global 
Severity Assessment   X     X 
Investigator Global Impression of Change  & Subject Global 
Impression of Change        X 
Consent for Study Exit Interview11  X      
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 22 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020    
 Safety Follow -up  
 Visit 7  
Week 16  TC 
(Day 113 ± 7 days)  Visit 8  
Week 20  TC 
(Day 141 ± 7 days)  Visit 9  
Week 24/ET2  
(Day 169 ± 7 days)  
Scarring/Keloid Assessment    X 
Record Adverse Event (AE) and Concomitant Medications10 X X X 
Household status of MC10 X X X 
Investigator Global Severity Assessment & Subject Global Severity Assessment    X 
Investigator Global Impression of Change & Subject Global Impression of Change    X 
1 Screening and Baseline may occur on the same day. If this occurs, lesion count and review of inclusion/exclusion criteria wil l only occur once.  
2 All visit dates are in reference to Baseline (e.g. Week 2 occurs 14 days after Baseline Visit ). The Week [ADDRESS_34221] terminates early, an in -clinic visit is preferred, but 
a remote visit may be performed with sponsor approval.  
3 Lesion counts will be performed twice during the  Baseline visit; the first assessment will be performed by [CONTACT_34651], and the second assessment will be 
performed by [CONTACT_34652] i mage evaluation. 
5 The physical exam will include a directed examination of the skin (presence or absence of individual features of erythema, fl aking/scaling, crusting, swelling, 
vesiculation/pustulation, and erosion/ulceration.  
[ADDRESS_34222] -menopausal (at least 12 months of continuous amenorrhea without an alternative medical cause), or surgically 
sterilized (documented hysterectomy, documented bilateral salpi[INVESTIGATOR_1656], or documented bilateral oophorectomy) . Tubal ligation does not meet the definition of surgically 
sterile.  
[ADDRESS_34223] -dose during the visit , regardless of whether lesions are present and whether study drug 
is applied.    
9 Study drug application will occur in clinic at Baseline , Week 2, Week 4, Week 8,  and Week 12. On days when a remote visit will occur, subjects/caregivers will not apply the 
study drug until the study visit so that the mixing/application of study drug can be observed by [CONTACT_34653].  
[ADDRESS_34224]/caregiver at a later date.   
NOTE: The  Week 4 visit  can be performed in clinic or remote. Baseline, Week 2,  Week 8, Week 12, and Week 24 should be performed in clinic wherever possible. Day 2, Week 
16, Week 20 should be performed as telephone contacts. Unscheduled visits are permitted as needed for medical reasons. In -clinic unscheduled visits should be reserved for 
evaluation of adverse events, lesion clearance,  and study drug dispensation as needed. Remote unscheduled visits may be utilized as well  as/if applicable. 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 23 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   2 INTRODUCTION 
2.1 Background 
Molluscum contagiosum (MC) is a common skin disorder that aﬀects mainly healthy children 
(Dohil et al., 2006).  MC has the greatest incidence in individuals aged 1–14 years ( Schofield et 
al., 2011) ; prevalence in children is between 5% and 11%  (FDA, 2020).  
MC virus is an important human skin pathogen and can cause disﬁgurement and suff ering in 
children . In adults, MC  is less common and often sexually transmitted. Extensive and persistent 
skin infection with the virus can indicate underlying immunodeﬁ ciency . MC virus is distinct 
from other poxviruses because of its host and tissue adaptations. It infects only the skin and, rarely, the mucous membranes. The virus has developed efficient mechanisms to grow in 
differentiating cells of the human epi[INVESTIGATOR_34596] ( Chen et al., 
2013).   
Patients with atopic dermatitis (AD) have an impaired skin barrier in addition to immunological 
changes which could explain the rising prevalence and high number of lesions in this population. 
Topi[INVESTIGATOR_34597] (both local immunosuppressants commonly 
applied to the skin in patients with atopic dermatitis) have been implicated as contributing factors in some patients  (Olsen et al., 2014).  
MC is transmitted between human hosts by [CONTACT_34654]. According to a prospective community cohort study ( Olsen et al., 2015) , the mean time to 
resolution was 13.3 months (SD 8.2). Eighty (30%) of 269 cases had not resolved by 18 months; 36 (13%) had not resolved by 24 months. Transmission to other children in the household occurred  in 102 (41%) of 250 cases in the literature.  
Novan, Inc. (Novan)  conducted Study NI-MC201, a phase 2, multi- center, double -blind, vehicle-
controlled ascending dose, 12- week st udy to assess the tolerability, safety, and efficacy of SB206 
in subjects with molluscum contagiosum. In this study, the safety and efficacy of SB206 was evaluated in 256 subjects, males and  females, 2 years of age or older, with 3 to 70 MC lesions. 
Differ ent concentrations and dosing frequency of SB206 were tested for up to 12 weeks and the 
number of the subjects of each dose group were: 47 (4% BID), 48 (8% BID), 47 (12% BID), 48 (12% QD) and 66 (Vehicle). In the intent -to-treat (ITT) analysis, 37.5% of subjects achieved 
complete clearance when treated with SB206 12% QD, compared to 18.2% of subjects achieving complete clearance with vehicle BID/QD combined (p=0.024). 
Based on the clear treatment effect demonstrated in NI-M201,  Novan conduct ed two phase 3 
multi-c enter, randomized, double-blind, vehicle-controlled, parallel group studies  of SB206 in 
subjects 6 months of age and older with molluscum contagiosum, NI -MC301 and NI -MC302. In 
NI-MC301, 352 subjects were randomized across 33 sites in the United Sta tes and had an 
average of 18.1 molluscum lesions at baseline and an average of age 7.1 years. The study 
discontinuation rate was 15.3%. In NI -MC302, 355 subjects were randomized across 33 sites in 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 24 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   the [LOCATION_002] and had an average of 18.3 molluscum lesions  at baseline and an average age 
of 6.5 years. The study discontinuation rate was 17.2% .  
The primary endpoint for these studies wa s the proportion of subjects in the ITT population with 
comp lete clearance of all treatable m olluscum lesions at Week 12 . Subjects with missing Week 
12 lesion count data were counted as non-responders. In NI -MC301, 25.8%  achieved complete 
clearance at Week 12 with  SB206 and 21.6% achieved complete clearance at Week 12 with 
Vehicle; 30.0% of subjects on SB206 and 20.3%  of subjects on Vehicle in NI-MC302 achieved 
complete clearance at Week [ADDRESS_34225] hoc analysis shows a continued trend of effectiveness by [CONTACT_34655] a complete clearance of 27. 9% for S B206 and 20.9% for vehicle (p= 0.0387). 
Based on these results , an additional phase 3 study, NI-MC304, is being conducted with SB206. 
Topi[INVESTIGATOR_34598] 1- 16% have been 
studied. Over [ADDRESS_34226] been exposed to Vehicle and over 3,400 exposed to 
berdazimer sodium as of January 31, 2020. In clinical studies completed to date, topi[INVESTIGATOR_34599] -tolerated with no safety concerns 
identified.  Note that description of the concentration of SB products used nominal numbers 
based on percent berdazimer sodium historically. Novan has updated the naming convention to 
use percent berdazimer. Therefore, SB 206 12% (nominal berdazimer sodium) is the same 
admixture formulation as SB206 10.3% (berdazimer). In this protocol, the nominal berdazimer 
sodium numbers remain in historical studies.  
2.1.1 Target Indication and Population 
SB206 is being developed to treat molluscum contagiosum in children and adults. 
2.1.2 Description of SB206  
SB206 is a topi[INVESTIGATOR_34600] , formed by [CONTACT_34656]. Berdazimer gel is a nitric 
oxide-releasing macromolecule containing covalently bound N- diazeniumdiolate nitric oxide 
donors; nitric oxide release from the macromolecule is initiated by [CONTACT_34657]. A summary  of nonclinical and clinical data is pr ovided below; additional details 
are provided in the Investigator’s Brochure . 
[IP_ADDRESS] Administration Regimen  
Subjects will apply treatment once daily for up to [ADDRESS_34227] has cleared, treatment should be resumed. No further treatment will occur after 
Week 12.  
An increase in the number of MC lesions (with or without inflammatory reaction) during the 
early treatment period is often observed. It is important to instruct the subjec t/caregiver to treat 
the new lesions as well as the existing lesions.  
Each dose will consist of berdazimer gel or vehicle gel with hydrogel thoroughly mixed together by [CONTACT_34658] a supplied dosing guide and applied to the individual lesio ns. 
Periocular lesions will be treated if the lesions are at least [ADDRESS_34228] has more than 20 MC, a second dose of berdazimer gel or vehicle gel with hydrogel can 
be prepared to ensure appropriate coverage of all lesions.  
[IP_ADDRESS] Justification for Dosing Strategy 
Based on totality of the data  presented in Section 2.1, SB206 12% QD  (now SB206 10.3% QD)  
was selected for this phase 3 study. 
2.1.3 Supportive Nonclinical Data 
Novan has completed over 150 non-clinical studies during the development of multiple  
berdazimer sodium products (SB204, SB206, SB208, SB414) to assess pharmacology, PK, 
ADME, and toxicology. For additional nonclinical information refer to the Investigator’s 
Brochure  (IB).  
2.1.[ADDRESS_34229] been treated with 
topi[INVESTIGATOR_34601] (SB204, SB206, SB208, SB414) and over [ADDRESS_34230] been 
no clinically significant changes in physical examination in subjects treated with topi[INVESTIGATOR_34602]; however, there have been a few sporadic clinically significant changes identified in laboratory assessments and vital signs.  
[IP_ADDRESS] Clinical Pharmacology and Pharmacokinetics 
The systemic bioavailability of SB206 after dermal administration has been investigated in  one 
maximal use stud y, NI -MC101 in patients, at least six months of age, with a minimum of [ADDRESS_34231] (hMAP3), a silicon 
containing component of the parent compound was noted. Fu rther PK analysis of Day 15 
samples indicated two subjects demonstrated negligible systemic concentration of hMAP3: one 
showed one measurable time point with 5.12 ng/mL at [ADDRESS_34232] dose among 3 time points (pre-dose, 1, and [ADDRESS_34233] dose), and the other showed 4 measurable time points with the 
maximum concentration of 33.9 ng/mL at [ADDRESS_34234] dose among 4 time points (pre -dose, 1, 3, 
and [ADDRESS_34235]-dose). Plasma nitrate concentrations were wi thin normal variability.  The 
maximum recorded post- Baseline value for methemoglobin of the study was 2.8%, and 
methemoglobin values from the 2 subjects who showed systemi c exposure did not exceed 2.2 %.  
In the NI-MC201 study, plasma hMAP3 concentrations in all PK blood samples at Week 12 or end or treatment were below the lower limit of quantitation (LLOQ).  
In addition, two other supportive studies with the berdazimer dru g product SB204 have been 
conducted in adults and adolescent subjects with moderate to severe acne vulgaris, and no 
quantifiable systemic exposure was observed. In adult subjects with moderate to severe acne 
vulgaris (NI-AC101) administration of SB204 8% ( berdazimer sodium  gel 16% co- administered 
with hydrogel) or Vehicle Gel daily for [ADDRESS_34236], back, upper shoulders twice daily (BID) (17% body surface area [BSA]) showed no detectable systemic exposure on Day [ADDRESS_34237] ( hMAP3 ), a silicon containing 
component of the parent compound. There was no noticeable difference in systemic nitrate levels 
on Day 1 or Day 5 in subjects treated with SB204 or Vehicle Gel and no evidence of accumulation. Likewise, in an open-label pharmacokinetic (PK) study (NI-AC103) in adolescents (ages 9 -16 years) with m oderate to severe acne v ulgaris, SB204 4% was applied 
topi[INVESTIGATOR_34603] (QD) for 21 days to 17% BSA and again no detectable systemic exposure to hMAP3 and no plasma nitrate concentrations outside of normal variability and negligible accumulation of nitrate after [ADDRESS_34238], randomized, double-blind, cross-over study examining 
electrocardiogram (ECG) effects following SB204 application (NI-AC104), there was no 
quantifiable systemic exposure to hMAP3 and no difference in plasma nitrate levels in 48 subjects with moderate to severe acne treated with SB204 (berdazimer sodium ) 4%, SB204 
(berdazimer sodium ) 12% or Vehicle Gel applied to 17% BSA . No changes in ECG were 
observed with therapeutic or supratherapeutic doses of SB204. 
In a 2 -week atopic dermatitis (AD) study (NI -AD101), and a 4-week psoriasis study (NI -PS101), 
a limited number of subjects who received SB414 6% (berdazimer sodium ointment 12% co-
administered with buffered hydrogel) demonstrated quantifiable systemic exposure to the study 
treatment at limited time points. Although both SB206 and SB414 have the same active 
pharmaceutical ingredient, the formulations are different: SB206 is a gel and SB414 is a cream. The cream formulation of SB414 resulted in low and not quantifiable systemic exposure to hMAP3 observed in the NI-AD101 and NI-PS101 studies for all but [ADDRESS_34239]-
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 27 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   dose. Note that SB414 formulation is cream while SB204 formulation is gel, similar to SB206. 
For more information, refer to the  Investigator’s Brochure.  
[IP_ADDRESS] Clinical Safety  
It should be noted some subjects have experienced transient asymptomatic erythema at the 
application site within 5 minutes of dosing, which typi[INVESTIGATOR_34604] ≤15 minutes . This is due to 
nitric oxide’s vasodilatory pharmacologic effect and is an expected event.  
Summaries of the safety analyses  of the phase 3 studies ( NI-MC301 and 302) are ongoing, and 
the CSRs are under preparation. The treatment emergent adverse event (TEAE) profile of SB206 
through the Week 24 was found to be favorable and was very similar between the two studies. Study drug discontinuations in the SB206 treatment arm were all due to application site reactions 
and no treatment- related serious adverse events were reported across both studies.  
Table 2 Overall Summary of TEAEs (Safety Population) through Week 24  
 NI-MC301 NI-MC302 
 Vehicle  
(n=116)  SB206 
(n=235)  Vehicle  
(n=117)  SB206 
(n=237)  
Subjects who reported at least one TEAE  36 (31.0%)  115 (48.9%)  30 (25.6%)  120 (50.6%)  
Serious TEAE  0 0 1 (0.9%)  1 (0.4%)  
Treatment -related TEAE  19 (16.4%)  86 (36.6%)  8 (6.8%)  86 (36.3%)  
TEAE leading to study drug discontinuation  1 (0.9%)  7 (3.0%)  1 (0.9%)  17 (7.2%)  
The TEAEs reported in greater than 5% of subjects in the SB206 treated groups were application 
site pain and application site erythema, with the majority of these TEAEs being mild or moderate in severity.  
Table 3 TEAE s in ≥ 2% of sub jects in either SB206 treated group or Vehicle group 
(NI-MC301)  
 Vehicle (n=116)  SB206 (n=235)  
 Mild  Moderate  Severe Mild  Moderate  Severe 
Application site pain  8 (6.9%)  0 0 34 (14.5%)  16 (6.8%)  1 (0.4%)  
Application site erythema  2 (1.7%)  1 (0.9%)  0 13 (5.5%)  15 (6.4%)  1 (0.4%)  
Application site pruritus  0 0 0 8 (3.4%)  2 (0.9%)  1 (0.4%)  
Pyrexia  3 (2.6%)  1 (0.9%)  0 7 (3.0%)  4 (1.7%)  0 
Application site exfoliation  0 0 0 4 (1.7%)  5 (2.1%)  1 (0.4%)  
Application site scar  9 (7.8%)  0 0 6 (2.6%)  0 0 
Application site swelling  1 (0.9%)  0 0 5 (2.1%)  1 (0.4%)  0 
Application site dermatitis  1 (0.9%)  0 0 1 (0.4%)  3 (1.3%)  1 (0.4%)  
Application site discolouration  0 0 0 5 (2.1%)  0 0 
Vomiting  1 (0.9%)  0 0 2 (0.9%)  5 (2.1%)  [ADDRESS_34240] infection  2 (1.7%)  0 0 3 (1.3%)  2 (0.9%)  0 
 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 28 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020    
Table 4 TEAEs in ≥ 2% of subjects in either SB206 treated group or Vehicle group 
(NI-MC302) 
 Vehicle (n=117)  SB206 (n=237)  
 mild moderate  severe mild moderate  severe 
Application site pain  1 (0.9%)  1 (0.9%)  0 15 (6.3%)  22 (9.3%)  0 
Application site erythema  0 0 0 10 (4.2%)  14 (5.9%)  2 (0.8%)  
Application site dermatitis  1 (0.9%)  0 0 6 (2.5%)  5 (2.1%)  0 
Application site scar  10 (8.5%)  0 0 10 (4.2%)  0 0 
Application site exfoliation  0 0 0 3 (1.3%)  5 (2.1%)  1 (0.4%)  
Application site pruritus  1 (0.9%)  1 (0.9%)  0 3 (1.3%)  5 (2.1%)  0 
Application site swelling  0 0 0 1 (0.4%)  5 (2.1%)  1 (0.4%)  
Pyrexia  2 (1.7%)  0 0 5 (2.1%)  2 (0.8%)  0 
Application site vesicles  0 0 0 0 5 (2.1%)  [ADDRESS_34241] 0 0 0 3 (1.3%)  3 (1.3%)  0 
 
Additional de tails regarding safety are available in the Investigators Brochure  (IB) . 
[IP_ADDRESS] Clinical Efficacy  
Recently two phase [ADDRESS_34242] been completed and the clinical study reports are under 
preparation. The primary efficacy endpoint for the studies was  complete clearance of all treatable 
MC lesions at Week 12 in the ITT population. The proportion of subjects with complete clearance 
at each visit is shown in  Figure 2 and Figure 3. 
Figure 2 NI-MC301: Percentage of Subjects with Complete Clearance  
 
Note: Subjects with missing lesion count data at the Week of interest were counted as non -responders.  0.0%4.3%10.3%21.6%
0.4%4.7%15.3%25.8%
0.0%5.0%10.0%15.0%20.0%25.0%30.0%35.0%
W eek 2 W eek 4 W eek 8 W eek 12Ve h ic le SB206
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 29 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Figure 3 NI-MC302: Percentage of Subject s with Complete Clearance  
 
Note: Subjects with missing lesion count data at the Week of interest were counted as non -responders.  
The proportion of subjects with complete clearance of all treatable molluscum lesions at Week 
12 in NI -MC301 was 25.8% for SB206 and 21.6% for vehicle (p=0.375) and 30.0% for SB206 
and 20.3% for vehicle (p=0.062) in NI -MC302. For the secondary endpoint, the proportion of 
subjects with complete clearance of all treatable molluscum lesions at Week 8 in NI -MC301 was 
15.3% for SB206 and 10.3% for vehicle (p=0.202) and 13.9% for SB206 and 5.9% for vehicle (p=0.028) in NI-MC302. The results of other endpoints are available in the IB. The Kaplan -
Meier analysis in both studies also support the effectiveness of SB206 by [CONTACT_34659].  
Analysis of the integrated da ta from NI-MC301 and NI- MC302 resulted in statistically 
significance for complete clearance at Week 12 (p= 0.038). Analysis of data from NI-MC302 study demonstrated substantial effectiveness for reducing lesions to 1 or 0 (p=0.011) and reducing lesions by [CONTACT_2669] 90% (p=0.002). SB206 demonstrated statistical effectiveness in 
complete clearance for up to 28%, reduced lesions to 1 or 0 for up to 39% and approximately 
37% of subjects achieved a 90% reduction in lesions in NI -MC302. In addition, subjects treat ed 
with SB206 showed a lower occurrence of scarring when compared to the vehicle arm. Molluscum, caused by a family of pox viruses, is known to occasionally heal with small pi[INVESTIGATOR_22940] 
(scar formation).”  0.0%1.7%5.9%20.3%
1.3%3.4%13.9%30.0%
0.0%5.0%10.0%15.0%20.0%25.0%30.0%35.0%
W eek 2 W eek 4 W eek 8 W eek 12Ve h ic le SB206
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 30 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   2.1.5 Benefit: Risk  Assessment  
Subjects may not expect to receive direct benefit from study drug treatment during study 
participation . This study is designed to provide information about the efficacy and safety of an 
investigational medication compared to placebo/vehicle.  
There is a theoretical risk of methemoglobin emia resulting from dermal application of NO, i.e., 
through NO binding with systemic hemoglobin and thus methemoglobin levels have been closely 
monitored in Novan clinical trials. There have been no reports of methemoglobinemia or 
observed methemoglobin le vels greater than 4.7% in subjects treated with topi[INVESTIGATOR_34605]. Fluctuations in methemoglobin during treatment have been similar in subjects treated with berdazimer sodium or vehicle. Methemoglobin increases following 
treatment are rare. In subjects treated with berdazimer sodium, there have been a few sporadic 
clinically significant changes identified in laboratory assessments and vital signs. There have been no clinically significant changes in physical examination. No rela ted SAEs have been 
reported for berdazimer sodium. 
Based on the known mechanism of action of NO as a vasodilator, theoretical risks from systemic 
exposure after topi[INVESTIGATOR_34606]. 
There have been no reports of hypotension and no clinically significant changes in vital signs (blood pressure, pulse) judged by [CONTACT_34660]. Reported rates of headache in the 
clinical development program to date are similar across berdazimer and vehicle-treated subj ects.  
Note that  transient asymptomatic erythema at the application site within 5 minutes of dosing, 
which typi[INVESTIGATOR_34607] ≤15 minutes , is an expected  sign. This is due to nitric oxide’s vasodilatory 
pharmacologic effect.  
2.[ADDRESS_34243] patients with MC are 
healthy young children. Ablative treatment often causes fear to the children and interferes in physician- patient relationships. Repeated ablative treatments are difficult. Procedura l treatments 
as well as self -limiting resolution may result in scarring. Using anesthesia involves safety risk 
and costs. Not treating increases the potential of further dissemination of the disease. Prevention of further dissemination of the disease is also important from a public health perspective. Topi[INVESTIGATOR_34608]206 may accelerate resolution of MC without causing pain and/or scarring, decrease the frequency of ablative treatment, and provide an effective, convenient treatment 
option for patients with MC.  
 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 31 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   3 OBJECTIVES AND ENDPOINTS  
Tier Objectives  Endpoint (s) 
Primary  
Efficacy  To evaluate the efficacy of 
SB206 10.3 % as compared 
to Vehicle in subjects with molluscum contagiosum  The proportion of subjects with complete clearance of all treatable MC at Week 12  
Secondary Efficacy Endpoints  To evaluate the efficacy of SB206 10.3 % as compared 
to Vehicle in subjects with molluscum contagiosum  • Proportion of subjects achieving a lesion count of 0 or 1 of all 
treatable MC at Week 12 
• Proportion of subjects achieving at least a 90% reduction from Baseline in the number of all treatable MC at Week 12  
• Proportion of subjects with complete clearance of all treatable MC at Week 8  
• Percent change from Baseline in the number of all treatable MC 
at Week 4  
Safety endpoints  To evaluate the safety of SB206 10.3% compared to Vehicle in subjects with molluscum contagiosum  • Incidence of treatment -emergent  adverse events  
• Change from Baseline in LSR scores  
• Change from Baseline in abbreviated physical examinations  
• Concomitant medications reportedProportion of subject(s) with reported scar(s)  
Other Endpoint  To evaluate BOTE and SB206 10.3% compared to Vehicle in subjects with molluscum contagiosum  • Change from Baseline in BOTE scores  
Exploratory  
endpoints  To evaluate various efficacy  and other 
parameters  of SB206 
10.3% compared to 
Vehicle in subjects with 
molluscum contagiosum.  • Percent change from Baseline in number of treatable MC at 
each visit (Weeks 2, 8, 12)  
• Proportion of subjects achieving a lesion count of 0 or 1 of all 
treatable MC at Week s 2, 4 and 8  
• Proportion of subjects achieving at least a 90% reduction from Baseline in the number of all treatable MC at Weeks 2, 4 and 8  
• Proportion of subjects achieving at least a 75% reduction from Baseline in the number of all treatable MC at Weeks 2, 4, 8 and 12 
• Absolute  change from Baseline in number of treatable MC at 
Weeks  2, 4, 8  and 12 
• Proportion of subjects with complete clearance of all treatable MC at Week 2 and Week 4  
• Time to complete clearance of all treatable MC  
• Proportion of subjects who have a recurrence of MC after the first visit at which complete clearance was observed  
• Subject -reported spread to household members as measured by 
[CONTACT_34661] (Weeks 2, 4, 8, 12)   
• Investigator Global Severity Assessment at Baseline, Week 12 
and 24  
• Subject Global Severity Assessment at Baseline, Week 12 and 
24 
• Investigator Global Impression of Change  at Week 12 and 24  
• Subject Global Impression of Ch ange at Week [ADDRESS_34244] safety while  protecting the integrity of the clinical trial data . 
In alignment with the FDA’s recommendation to utilize electronic and remote methods, the NI -
MC304 study was designed to include remote tech nology for the study visits between Week 2 
and Week 12, our primary endpoint, in an effort to minimize the amount of time that subjects 
and caregivers are required to be present in clinic if necessary , while  also minimizing the number 
of contacts for our site personnel ( FDA, 2020). Subjects /caregivers and investigators will 
practice at least one (simulated) remote assessment  at the Baseline visit to familiarize each party 
with the technology before the first remote use. The frequency of planned on- site monitoring 
visits will be reduced, and more frequent remote monitoring visits will be incorporated to support protection of all team members. Enhan ced central monitoring, telephone contact [CONTACT_34662], trial participant status, and study progress, or remote monitoring of individual enrolled trial participants, will be performed as outlined in the 
monitoring plan. Additio nal information will be captured on any protocol deviations that occur 
due to COVID-19. Finally, a clinical  trial continuity  plan has been established for situations to 
outline the current modifications in place and in case of further impact the existing  study design 
and plans. The plan incorporates contingency measures for additional disruptions due to COVID-19 and other unforeseen circumstances, provides a process for documenting any participants 
impacted by [CONTACT_34663]. The sta tistical analysis plan (SAP) 
includes analyses that will be performed to address the impact of the implemented contingency measures, and any necessary ad hoc analyses not incorporated into the SAP will be discussed in 
the clinical study report.  
This is a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study 
to be conducted in approximately 850 subjects with MC. After obtaining informed consent/assent, subjects who satisfy entry criteria will be randomized 1:1  (active:vehicle)  using 
an interactive web response system (IWRS) . Subjects receiving current treatment for MC at the 
time of the Screening  Visit will enter a wash out period of up to 14 days prior to randomization. 
In the event no wash out period is required, Screening and Baseline visit activities may be combined into a single in -clinic visit. At randomization, subjects will be stratified b y investigator 
type (dermatologist vs. other), the subject’s BOTE score at Baseline (no inflammation (BOTE = 0) vs. mild/moderate/severe inflammation (BOTE ≥ 1) and number of randomized subjects per household ([ADDRESS_34245] per household vs. 2 subjects per household). Subjects will be stratified to [ADDRESS_34246] individually meet all inclusion/no exclusion 
criteria. For subjects in the same household, Screening can occur on different days; however, the 
Baseline visit must occur on t he same day.  Households randomizing two  subjects will receive the 
same treatment assignment for both subjects.  
Subjects or their caregivers will apply SB206 10.3 % or Vehicle Gel once daily for a minimum of 
4 weeks and shall continue unless otherwise instructed by [CONTACT_34664] 12 weeks to all lesions identified at Baseline and new treatable lesions that arise  during the course of the study. 
Subjects or their caregivers will continue to treat the area until the next scheduled visit even if 
the lesi on(s) clear.  At each in -clinic and remote visit, the investigator will count and record the 
number of active (raised, treatable) molluscum lesions per body area. Complete clearance should 
be confirmed by [CONTACT_28920]-clinic lesion count before treatment is discontinued. If the investigator determines all lesions a re cleared at a visit, the investigator may instruct the subject to stop 
treatment . If treatment is stopped due to clearance, subjects will continue regularly scheduled 
visits through Week 12/ET and all procedures outside of study drug activities should be continued. If lesions recur or new lesions occur between visits after being stopped due to 
clearance, the subject or caregiver should re -initiate treatment to the recurring  and new lesions. A 
new kit should be dispensed at Weeks [ADDRESS_34247]/caregiver to resume treatment.  No study treatment is planned to be dispensed after the 
Week [ADDRESS_34248]/caregiver will be instructed on the technology to be used for remote  visits . After the 
initial molluscum lesion count is completed, it will be repeated by [CONTACT_34665]/caregiver using the subject/caregiver’s electronic device that will be utilized to capture photographs for remote  visits. This will provide the s ubject/caregiver an opportunity to practice 
with the technology and will allow for the assessor to understand lesion appearance in person compared to through the technology platform.  
Subjects  will be contact[CONTACT_34666] [ADDRESS_34249] information on early dose 
reactions. At Weeks 16 and 20, subjects will be contact[CONTACT_34646] (AEs); at Week 24, the subject will be seen at the 
site for a final study visit to assess scarring, keloid, and MC recurrence.  
Subjects who discontinue the study prior to the Week 12 visit will be asked to complete the Week 
12 visit assessments in the clinic ; this will be recorded as an Early Termination (ET 1) visit. 
Subjects who discontinue from the study after Week 12 but prior to Week 24 will be asked to come 
to the site to complete Week 24 assessments; this visit will be recorded as an ET2 visit.  
Safety assessments include BOTE Inflammation Scores, Local Skin Reaction (LSR) s cores, 
adverse event collection, including scarring/keloid and urine pregnancy tests (UPTs). Safety 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 34 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   assessments will be completed at specified visits through Week 12. Adverse events and 
concomitant medicat ions will be reviewed and updated as needed at each  visit through Week 24.  
Inflammatory reactions around MC lesions has been associated with imminent resolution of MC 
(sometimes referred to as “beginning-of-the-end” [“BOTE”] sign). The investigator (or designated evaluator) will assess the presence and overall degree of inflammatory reactions at 
MC lesions at Baseline (pre-dose) and Weeks 2- 12 using the BOTE Inflammation S core 
(Section [IP_ADDRESS]) . BOTE m ay be associated with itch, but not pain. BOTE is usually 
asymptomatic, self -limited, localized to individual MC lesions, and does not require 
discontinuation of study treatment or additional treatment. LSR is generally more diffuse, associated with signif icant itch or tenderness, may necessitate discontinuation of study treatment,  
and may need treatment for symptomatic relief (e.g. a topi[INVESTIGATOR_34609]). For very severe LSR s, systemic corticosteroids may be considered ( Section 7.2.3 for 
additional details) . Investigators will assess the treatment area at each scheduled visit and use 
their medical judgement to differentiate b etween BOTE and LSRs. BOTE Inflammation Score 
and LSR component scores will be recorded at each visit. When LSRs are clinically significant at the application site, the investigator should report the condition as AE(s). 
Prior to the first application of study drug at Baseline, the investigator will assess the subject’s 
skin as part of the physical examination, including the presence or absence of individual features 
of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. At Baseline ([ADDRESS_34250]-dose) and at Week 2 through Week 12 the evaluators will rate LSRs 
on individual features including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration using the LSR Assessment sc ale (Table 7).   
Adverse events will be assessed and collected after the initiation of study drug treatment through the end of the subject’s last visit. Treatment- related adverse events and all serious adve rse events 
will be followed up until resolution or up to one year after last treatment, whichever occurs earlier.  
Scar formation (scars /keloids/hypertrophic scars) will be assessed starting at the Week 4 visit 
through Week 24. The investigator will map locations of the molluscum lesions at Baseline. 
Additional lesions identified through Week 12 will be added to the map. Using the map as a guidance, the investigator will assess the treated areas for scar/keloid formation. All scars, 
including keloid/hypertrophic scars, that develop after the Baseline assessment should be 
captured as AEs and assessed for relatedness to study treatment.   
If a subject’s treatment is discontinued by [CONTACT_34649], that AE should be indicated as the reason for treatment discontinuation. All subjects will be 
encouraged to remain in the study and to complete all required study visits throughout the 24-
week study duration. 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34251] (DSMB) will review all available  unblinded safety data 
(including completed patch testing results) . Section  11.2 provides additional details regarding the 
DSMB.   
4.2 Number of Participant s and Study Sites  
Approximately 850 male and female subjects ages 6 months of age and older with a minimum of 
3 and a maximum of 70 molluscum lesions  at Baseline will be enrolled at approximately 55 sites 
in the United Sta tes. 
4.3 Treatment Arms and Duration 
A double-blind randomization will be generated that randomly allocates subjects to one of 2 
treatment arms (SB206 1 0.3% or Vehicle gel) in a 1:1 ratio, so that approximately 50% of 
subjects will be randomized to receive SB206 10.3%  and 50% will be  randomized to receive 
Vehicle gel. Subjects receiving current treatment for MC at the time of the Screening Visit will enter a wash out period of up to [ADDRESS_34252] to the affected designated area(s).  Treatment will be applied  once daily to all lesions 
identified at Baseline and new lesions that arise during treatment for a  minimum of 4 weeks and 
shall continue unless otherwise instructed by [CONTACT_34664] 12 weeks. If the investigator determines all lesions are cleared at an in- clinic  visit, the investigator may stop treatment. If 
treatment is stopped due to clearance, subjects will continue regularly scheduled visits through Week 24/ET, and study drug will be dispensed in case of lesion recurrence between study visits. 
If lesions recur or new lesions occur between visits after bein g stopped due to clearance, the 
subject or caregiver should reinitiate treatment to the recurring and new lesions. At each visit, 
sites should remind subjects/caregivers that if new lesions or recurring lesions are noticed between visits, treatment should be applied to those new or recurring lesions. The subject or 
caregiver will apply to the individual lesions. Periocular lesions will be treated if the lesions are 
at least [ADDRESS_34253] satisfy all the following 
criteria:  
1. Be 6 months of age or older, and in good general health; 
2. Have a documented informed consent form signed by [CONTACT_34667] a parent or legal 
guardian and an assent form as required;  
3. Have between 3 and 70 treatable MC lesions at Baseline; 
4. For women of childbearing potential ( WOCBP ): Must have a negative urine pregnancy 
test prior to r andomization and must agree to use an effective method of birth control 
during the study; Note: WOCBP and effective methods of birth control are outlined in Section 9.4. 
5. Have a device (phone, tablet, personal computer, etc.) that will support remote visits, including a camera;  
6. Be willing and able to follow study instructions and likely to complete all study requirements , including remote study visits. 
5.3 Exclusion Criteria  
Subjects will not be eligible for entry into this study if they meet any of the following criteria:  
1. Have strongly suggested sexually transmitted MC and do not agree to refrain from sexual 
activities throughout the study period; 
2. Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive 
treatment; 
3. Have significant injury on and/or surrounding MC that may impact ability to treat and 
count lesions; 
4. Have received treatment with topi[INVESTIGATOR_34610] 2 
cm of MC lesions within 14 days prior to Baseline; 
5. Have received treatment for MC during the 14 days prior to Baseline with podophyllotoxin, imiquimod, cantharidin, sinecatechins, topi[INVESTIGATOR_22775], oral or topi[INVESTIGATOR_34611], or other homeopathic or over the counter (OTC) products including, but not limited 
to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor antagonists 
(including Zantac), or any agent that in the opi[INVESTIGATOR_2511] i nvestigator may be relevant – 
(e.g. w art therapi[INVESTIGATOR_014] );  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34254] received surgical procedures related to MC (e.g. cryotherapy, curettage) within 14 
days prior to Baseline; 
7. Have MC only in periocular area;  
8. Female subjects who are pregnant, planning a pregnancy or breastfeeding; 
9. Have known hypersensitivity to any ingredients of SB206 or Vehicle Gel including 
excipi[INVESTIGATOR_840];  
10. Have participated in a previous study with a berdazimer containing product (i.e. SB204, 
SB206, SB208, SB414);  
11. Have more than one other family member participating in this stu dy (NI-MC304); 
12. Have at least [ADDRESS_34255] (i.e. SB204, SB206, SB208, SB414); 
13. Have participated in any other trial of an interventional investigational drug or device 
within 14 days or concurrent participation in another interventional research study; 
14. History or presence of clinically significant medical, psychiatric, or emotional condition that, in opi[INVESTIGATOR_871], would compromise the safety of the subject or the 
quality of the data. 
5.[ADDRESS_34256] Screening  
Written informed consent (including assent form where required) will be obtained before any 
study-related procedures are performed. The investigator may discuss the study and the 
possibility for entry with a potential subject/caregiver without first obtaining consent and/or 
assent. A hard -copy or electronic informed consent may be utilized. A subject wishing to 
participate must give documented informed consent/assent prior to any study- related procedures 
being conducted, including those performed solely for the purpose of determining eligibil ity for 
study participation or withdrawal from current medication (if required prior to study entry). The 
investigator has both the ethical and legal responsibility to ensure that each subject being 
considered for inclusion in this study has been given a full explanation of the procedures and expectations for study participation.  
The site -specific informed consent forms (ICF)/assent forms must be forwarded to the CRO for 
approval prior to submission to an Institutional Review Board (IRB) and/or Independent Ethics 
Committee (IEC) as appropriate, in cases in which a local IRB is being used. Each subject will sign the ICF that has been approved by [CONTACT_34668]. Each ICF/assent form must adhere to the ethical principles stated in the Declaration of Helsinki and 
will include the elements required by [CONTACT_7214] (FDA) regulations in 21 
CFR as well as the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and applicable federal  and local regulatory requirements. The ICF/assent 
form(s) must also include a statement that Novan and the CRO (or their designees) and auditing 
regulatory agencies will have direct access to the subject’s records and medical history. 
Once the appropriate essential information has been provided to the subject/caregiver and fully 
explained by [CONTACT_093] (or a qualified designee) and it is felt that the subject/caregiver 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 38 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   understands the implications and risks of participating in the study, the IRB appr oved ICF/assent 
document shall be signed and dated by [CONTACT_34669]/caregiver and the person obtaining 
consent (investigator or designee), and by [CONTACT_34670]. The subject/caregiver will be given a copy of the signed ICF/assent document with the original kept on file by [CONTACT_093]. All the above activities must be 
completed before any study related procedures are conducted. 
5.5 Screen Failures  
Study site personnel will use an interactive web response system (IWRS) system to assign a 
unique study number to each potential study participant, following informed consent. Subjects 
that ultimately do not meet eligibility criteria or who withdraw their consent prior to 
randomization will be considered a S creen Failure. The site will document the Screen Failure 
status in the IWRS and in their source documents/eCRF and will document their demographics and reason for screen failure.  
5.6 Deviation from Inclusion/Exclusion Criteria  
Deviation from the inclusion/e xclusion criteria is not allowed. Any deviation identified during 
the study will be documented and should be discussed with the CRO and/or sponsor. 
[ADDRESS_34257]  
6.1 Study Procedures  
Subjects are expected to be in this study for up to 27 weeks. There is a 2- week 
screening/washout period if needed and the treatment period is expected to be a minimum of 4 weeks and a maximum of 12 weeks. After the 12 -week treatment period, subjects will enter a 12 -
week safety follow-up period . The Schedule of Assessments ( Table 1) summarizes the study 
procedures/assessments to be performed/collected at each study visit. Some Baseline/Day 1 
procedures (i.e. review of inclusion/exclusion criteria, brief physical examination including a 
directed assessment of skin condition prior to application of study drug, adverse event assessment, concomitant medication review, and UPT if applicable)  must be completed prior to 
randomization. Subjects who meet all eligibility criteria who do not require washout from any 
current treatment may be screened and randomized the same day. At Baseline, subjects at 
selected sites will have an opportunity to consent to a study exit interview. Once randomized, the subject/caregiver will be trained on the mixing, application, and storage of the study drug. The first application should be done at the clinic  as well as having in-clinic applications being 
performed at Week 2, Week 4 (if the visit is performed in the clinic), Week [ADDRESS_34258] s/caregivers will be observed mixing and applying study drug during each study visit 
through t he final scheduled dose of study drug during the Week [ADDRESS_34259] /caregiver  will assess the impact of MC at Baseline, Week 12, and Week 
24. The Investigator and subject/caregiver will also complete the global impression of change at 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34260] to complete the study. To achieve t his, Novan created an 
engagement and retention plan that includes the following, in addition to other supportive 
processes : 
• Remote visits , to decrease subject/caregiver burden and exposure 
• Daily dosing reminders and appointment reminders  
• Brief (1 -3 minute) e ducational videos, including training on normal lesion healing 
• Study- related retention items , provided at each visit  
• Certificate of participation  
• Travel and childcare reimbursement as needed  
• Site outreach to subject/caregiver after a missed visit  
• Standardized follow up letter process if subject/caregiver are unresponsive to contacts 
(Section  6.8.5) 
Additional details can be found in the Study Procedures Manual. This plan will continue to be 
revised as study circumstances evolve.  
6.3 Study Visit Scheduling  
At the end of each study visit the next visit should be scheduled/confirmed. Screening, B aseline, 
Week 2, Week 8, Week [ADDRESS_34261]. Every effort should be made to adhe re to the allowable study visit 
window period as described in the Schedule of Assessments ( Table 1). All visit dates are in 
reference to Baseline Day 1. In the event that a subject visit is performed out of window or if a 
visit is skipped, every effort should be made to get the subject to return for the next visit or 
complete the early termination visit if the subject is discontinuing from the study. A text 
messaging service or application may be utilized during the trial to send reminders and other educational messages to subjects/caregivers  throughout the course of the study. 
6.4 Remote Visits  
Week 4 can be performed as a remote visit or in clinic visit . All subjects/caregivers will be 
instructed on the technology to be utilized during the Baseline visit. Approximately 24-[ADDRESS_34262] visits outside of the ones specified 
in the Schedule of Assessments, in order to investigate a possible adverse event, follow up on 
adverse events, etc. The date and reason for the Unscheduled visit should be recorded in the source documents, with the specific procedures performed determined by [CONTACT_093], and in 
consultation with the m edical monitor as needed, depending on the reason for the visit. In -clinic 
unscheduled visits should be reserved for assessment or follow-up of AEs and dispensation of 
drug. Remote  visits can be used when possible. 
6.6 Order of Assessments  
At the Baseline visit on Day 1, the physical examination and BOTE Inflammation Score  should 
be done prior to randomization to study treatment. For WOCBP  (see definition in Section  9.4), 
the UPT must be done prior to randomization. The initial Local Skin Reaction (LSR) assessment should be done at least [ADDRESS_34263] convenient to perform lesion counting, 
mappi[INVESTIGATOR_007], and scarring assessments immediately following the BOTE and LSR assessments . In 
order to ensure consistent counting of MC lesions, t he same assessor sh ould complete the le sion 
counts at all visits, but at a minimum, at Baseline and Week 12.   
6.7 Study Procedures by [CONTACT_24326]  
6.7.1 Screening (Day –15 to Day 1) (In -Clinic  Visit ) 
The following procedures must be performed and recorded at the Screening visit: 
1. Review study procedures and information regarding the study including the potential risk and benefits of SB206 with the subject/caregiver and obtain documented consent/assent.  
2. Obtain demographic information. 
3. Obtain subject’s medical history (including start date of the subject’s current epi[INVESTIGATOR_34612] [i.e., when molluscum was first noticed by [CONTACT_423]/caregiver ]), household 
MC status, medication history, and concomitant medication information. 
4. Perform lesion mappi[INVESTIGATOR_34613].   
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34264] may not participate in the study.  
6. Review inclusion/exclusion to confirm whether subject qualifies to participate in the study. 
6.7.2 Visit 1/Baseline  (Day 1) (In -Clinic Visit)  
The following procedures must be performed and recorded at the Baseline visit. If Screening and 
Baseline visits occur the same day, procedures with an asterisk (*) should only be performed once 
and will be recorded as Baseline values.  
1. Perform a brief physical examination , including the directed examination of the skin 
(presence or absence of individual features of erythema, flaking/scaling, crusting, 
swelling, vesiculation/pustulation, and erosion/ ulceration ). 
2. Perform lesion mappi[INVESTIGATOR_34613].* 
3. Perform BOTE Inflammation Score (pre -dose). 
4. Complete Investigator Global Severity Assessment.  
5. Complete Subject Global Severity Assessment.  
6. Obtain UPT , as applicable. If pregnancy test is positive, the subject may not participate in 
the study.*  
7. Update concomitant medication information.  
8. Confirm eligibility and randomize subject.  
9. Provide subject diary and dispense study drug.  
10. Weigh and record study product tubes.  
11. Instruct and practice remote visit technology with subject/caregiver, preferably on the 
device that will be used for the duration of the study. The investigator should r eview and 
perform a lesion count with the captured images.  
12. Instruct subject on dispensing, mixing, and application of study product and diary 
completion. 
13. Have subject/caregiver apply first dose in clinic from kit assigned at randomization. 
14. Complete Local Skin Reaction assessment approximately [ADDRESS_34265] AE information for any AEs reported. 
16. Confirm household MC status (any new cases in household members since screening 
visit).*  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 42 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Note: Follow  up interviews will be performed  with a subset of subjects  that complete  Week 
12. Consent will be obtained between screening and the Week [ADDRESS_34266]/caregiver at a later date after Week 12 is completed.  
6.7.3 Visit 2/Day 2 ( Telephone Contact ) 
The following procedure must be performed and recorded at the Day [ADDRESS_34267] is feeling  and assess if any changes to AEs or 
concomitant medications . 
6.7.4 Visit 3/Week 2 (Day 15 ± 3 days) ( In-clinic Visit ) 
The following procedures must be performed and recorded at the Week 2 visit. 
1. Perform BOTE Inflammation Score.  
2. Complete Local Skin Reaction Assessment.  
3. Perform lesion counting and mappi[INVESTIGATOR_34614]. 
4. Review study drug compliance/diary completion.  
5. Review dosing instructions and observe the subject/caregiver apply daily dose using the kit assigned at randomization. 
6. Collect and record AE information for AEs reported. 
7. Update concomitant medication information  and confirm if any new occurrences of MC 
were reported in the subject’s household. 
6.7.5 Visit 4/Week 4 (Day 29 ± 5 days) ( In-clinic or Remote Visit)  
This visit can occur in clinic or be performed as a remote visit. If this visit is performed remotely, 
subjects/caregivers will upload images of all treatable lesions for the site to review  in advance of 
the visit. If additional images are required, the site will notify the subject and provide any necessary 
feedback. The remote visit should be rescheduled within visit window if acceptable images have 
not been received by [CONTACT_779]. Additional details on this process are found in the Study Reference Manual. I f this visit is performed in clinic, no images are required , and the visit procedures are 
expected to be completed while the patient is in clinic. The following procedures must be performed and recorded at the Week [ADDRESS_34268] recurrence of MC.  
5. Perform scarring/keloid assessment ; if present, document location  on lesion map  and 
record as an AE . 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 43 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   6. Weigh returned study drug and review study compliance.* 
7. Weigh, record, and dispense new supply of study product.* 
8. Review dosing instructions and observe subject/caregiver apply daily dose. 
9. Collect and record AE information for AEs reported. 
10. Update concomitant medication information  and confirm if any new occurrences of MC 
were reported in the subject’s household. 
* Note: If Visit [ADDRESS_34269]/caregiver can return the study 
drug ki t and receive a new kit after completion of the remote visit and within the 
established visit window. If Visit [ADDRESS_34270]/caregiver will 
return the study drug kit and will receive a new kit while in clinic.  
6.7.6 Visit 5/Week 8 (Day 57 ± 5 days) ( In-clinic Visit ) 
The following procedures must be performed and recorded at the Week [ADDRESS_34271] recurrence of MC.  
5. Perform scarring/keloid assessment; if present, document location on lesion map and 
record as an AE . 
6. Weigh returned study drug and review study compliance. 
7. Weigh, record, and dispense new supply of study product. 
8. Review dosing instructions and observe subject/caregiver apply daily dose. 
9. Collect and record AE information for AEs reported. 
10. Update concomitant medication information  and confirm if any new occurrences of MC 
were rep orted in the subject’s household. 
6.7.7 Visit 6/Week 12/ET (Day 85 ±5 days) (In -clinic Visit)  
The following procedures must be performed and recorded at the Week 12/ET visit. 
1. Obtain pregnancy test and evaluate results, as applicable.  
2. Perform BOTE Inflammation S core.  
3. Perform Local Skin Reaction Assessment. 
4. Perform lesion counts and update lesion map with location for any new lesions. 
5. If previously cleared, assess for subject recurrence of MC.  
6. Perform scarring/keloid assessment ; if present, document location on lesion map and 
record as an AE . 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34272]/caregiver administer final dose of study drug from previously dispensed kit  only i f 
lesions are present.  
11. Weigh returned study drug and review study compliance. 
12. Collect and record AE information for AEs reported. 
13. Update concomitant medication information  and confirm if any new occurrences of MC 
were reported in the subject’s household. 
14. Review interview  procedures with the subject/caregiver and obtain documented 
ICF/assent.  
Note: Follow up interviews will be performed  with a subset of subjects that complete Week 
12.  Consent will be obtained during the Week [ADDRESS_34273]/caregiver at a later date.  
6.7.8 Visit 7/Week 16 and Visit 8/Week 20 (Day 113 ±7 days; Day 141 ±7 days) (Telephone Contact ) 
The following procedures must be performed and recorded at the Week [ADDRESS_34274] information for new and ongoing AEs, including recurrence of MC . 
2. Confirm household MC status (any new cases in household members since last visit).  
3. Update concomitant medication information . 
6.7.9 Visit 9/Week 24 (Day 169 ± 7  days) (In -clinic Visit)  
The following procedures must be performed and recorded at the Week 24 visit.  
1. Perform scarring/keloid assessment; if present, document location on lesion map and 
record as an AE.  
2. Complete Investigator Global Severity Assessment and Investigator Global Impression of 
Change. 
3. Complete Subject/Caregiver Gl obal Severity Assessment and Subject Global Impression 
of Change. 
4. Collect and record information for new and ongoing AEs, including subject recurrence of MC. 
5. Confirm household MC status (any new cases in household members since last visit visit).  
6. Update co ncomitant medication information.  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34275]’s treatment will be discontinued. The investigator can 
discontinue the treatment for a subject at any time if medically necessary. If a subject’s treatment is permanently discontinued by [CONTACT_34671], that AE should be indicated as the reason for treatment discontinuation. In this case, the subject is discontinued from the 
treatment, but still pa rticipates in the study and the subject is encouraged to follow the visit 
schedule and complete all assessments , part icularly those at Week [ADDRESS_34276] experiences an LSR (AE) for the first time, the investigator must confirm if treatment 
is needed, if a treatment modification (hold treatment for certain areas) is needed, and/or if a 
treatment interruption (discontinue treatment in all areas) is needed. If the investigator confirms 
treatment is needed, the subject can continue study treatment on all areas, hold treatment in certain areas, or interrupt treatment completely, and add non- medicated treatment such as 
petroleum gel as a concomitant medication. This option can be exercised at any point during the 
study as needed.  
If no concomitant treatment is added, the investigator may choose to withhold study treatment on 
either specific areas (modification) or all areas (interruption) until the investigator confirms it is appropriate to continue. It is recommended to modify or interrupt treatment for 2-3 days before 
re-starting the study treatment; the investigator should use their discretion for when to reiniti ate 
treatment by [CONTACT_34672]/caregiver t o determine if the event 
is resolved or if continued modification/interruption of study treatment is necessary. The 
investigator will confirm when reintroduction of study treatment can occur. This option can be exercised at any point during the study as ne eded.  
For more severe AEs, concomitant treatment such as corticosteroids can be added while withholding study treatment on specific areas (modification) or all areas (interruption) until the investigator confirms it is appropriate to continue with the study drug. Similar to the modifications and interruptions above, it is recommended to modify or interrupt treatment for 2-
3 days before re-starting the study treatment; the investigator should discuss the status of the AE 
with the subject/caregiver to determine if the event is resolved or if continued modification/interruption of study treatment is necessary. The investigator will confirm when reintroduction of study treatment can occur. This option can also be exercised at any point during 
the study as needed. 
After the resolution of the first LSR  and reinitiation of treatment, if a more severe second LSR 
occurs, it is appropriate to suspect the cause is allergic contact [CONTACT_8748]. Study treatment on all 
areas should be discontinued, and after resolution of the second LSR, patch testing is 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34277]/caregiver consent s. This step should be exercised only if the LSR is 
more severe than previous LSR(s). See Appendix 1 for additional information. 
[IP_ADDRESS] Temporary Treatment Discontinuation 
The investigator may instruct the subject to temporarily hold treatment to a specified region or 
completely (i.e., due to an adverse event). This treatment modification and the reason for the temporary drug interruption should be documented in the subject’s source documents. The 
lesions in the impacted area should continue to be counted in the lesion count during the period 
of treatment modification. See Section  6.8.2 for additional details.  
[IP_ADDRESS] Permanent Discontinuation of Treatment 
The investigator may discont inue a subject’s treatment if the subject/caregiver has failed to 
follow study procedures or to keep follow-up appointments. Appropriate documentation in the 
subject’s study record and the study database regarding the reason for treatment discontinuation 
must be completed. See Section 6.8.2 for additional details.  
Reasons for an investigator’s withdrawal of a subject from the treatment  may include, but are 
not limited to, the following: 
• Safety (e.g., severe adverse reactions, pregnancy) 
• When a concomitant medication or treatment likely to interfere with the results of the 
study is reported, or required, by [CONTACT_423], the investigator will decide, in consultation 
with the CRO whether the subject is to be withdrawn. 
Reason(s) for discontinuation from the treatment as listed in the study record will be entered into 
the study database as follows: 
• Complete clearance confirmed by [CONTACT_34673] 12 
• Adverse Event (including LSRs deemed to be significant by [CONTACT_1697]) 
• Withdrawal of Consent by [CONTACT_27720]/Caregiver  
• Lost to Follow- Up 
• Other  
6.8.[ADDRESS_34278]/caregiver may voluntarily withdraw from study participation at any time. If the 
subject/caregiver withdraws consent and discontinues from the study, the investigator will 
attempt to determine the reason for discontinuation and record the reason in the subject’s study records and in the study database. In the event of discontinuation from the study prior to the 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34279] return to the study site to 
complete the Week 12 evaluations (ET 1 visit). If the subject/caregiver is unable or unwilling to 
return to clinic for the Week [ADDRESS_34280]’s study record and in the study database.  
All Week [ADDRESS_34281] is not 
able to atte nd other study visits.  
Study completion or reason(s) for discontinuation from the study as listed in the study record will be entered into the study database as follows: 
• Withdrawal of Consent by [CONTACT_27720]/Caregiver  
• Lost to Follow- Up 
• Adverse Event  
• Other  
Novan has the right to terminate or stop the study at any time. Should this be necessary, the investigator will ensure that proper study discontinuation procedures are completed. 
6.8.[ADDRESS_34282] to Follow -up 
All subjects who fail to return to the study site will be contact[CONTACT_34674](s) why the subject failed to return for the necessary visit or elected to discontinue from the study. If a subject/caregiver is unreachable by [CONTACT_34675] a minimum of three 
documented attempts (one attempt on three different days using at least 2 different forms of 
communication), a certified letter will be sent requesting that the subject contact [CONTACT_34676]. These actions will be reported on the subject’s study record and a copy of the follow- up letter 
maintained in the investigator's file.  The certified letter should include the following questions:  
• Please choose one of the following:  
o I/my child want to continue participating in this study.  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 48 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   o I/my child  am no longer interested in participating in this study and withdraw my 
consent. 
• At the time you chose to stop participating in study visits, was your/your child’s 
molluscum co ntagiosum:  
o Resolved (no lesions left) 
o Resolving (number of lesions is decreasing) 
o Unchanged (number of lesions is similar to previous visit) 
o Worsening (number of lesions increased) 
An investigator may withdraw a subject from the study when a subject is lost to follow -up. 
6.9 Study Termination  
Both Novan and the principal investigator [INVESTIGATOR_34615]’s site at any time. Should this be necessary, Novan or a specified designee will inform the appropriate regulatory authorities of the termination of the study and the reasons for its termination, and the principal investigator [INVESTIGATOR_34616]/IEC of the same. In 
terminating the study, Novan and the principal investigator [INVESTIGATOR_34617]’ interests. 
7 DESCRIPTION OF STUDY ASSESSMENTS  
The following study assessments will be done. Additional details can be found in in the Study 
Reference Manual and in the supportive online trainings. 
7.1 Efficacy  Assessments  
7.1.1 Molluscum Contagiosum Lesion Counts 
Molluscum contagiosum is a viral infection characterized by [CONTACT_34677], discrete, waxy, skin-colored, 
dome-shaped raised papules, an average of 3 –5 mm in diameter. The papules may be umbilicated 
and contain a caseous plug. When the lesions are squeezed or traumatized, a creamy, grey -white 
material can be extruded. If the investigator cannot clearly differentiate the lesions as is the case for agminated (clustered ) lesions this should be counted as one lesion. If the investigator can 
differentiate and count the umbilical tops separately,  each lesion should be counted separately. 
The investigator should be consistent with the method of recording agminated lesions throughout the study. 
For the purpose of this clinical trial, only treatable  MC lesions are counted. Treatable lesions are 
any active (raised, palpable) MC lesions that are dome -shaped, pearly,  and shiny white top 
centered papules that are at least [ADDRESS_34283] pass the study training including lesion 
count training. Training on how to accurately count the number of MC lesions will be provided.  
Mappi[INVESTIGATOR_34618]: At every visit from Baseline through Week 12, all lesions should be 
recorded on the body map and will clearly note the location of each lesion or agminated lesion. 
The lesion map is intended to assist study personnel in performing lesion counting and 
scar/keloid as sessment.  The body map will also be shared with the subjects/caregivers at Week [ADDRESS_34284] with counting of lesion s. 
Definition of Clearance : For the purpose of this study, “c lear” means  resolution of the active 
(raised, palpable) treatable molluscum lesion(s). After a lesion has cleared, the residual surface changes such as a pi[INVESTIGATOR_34619] (indentation), hyperpi[INVESTIGATOR_371], or hypopi[INVESTIGATOR_34620]. Additional details will be provided in the lesion count training. Complete clearance can only be confirm ed by [CONTACT_28920]-clinic lesion count. 
The same evaluator should perform lesion counts at Screening, Baseline, and Weeks 2, 4, 8 and 
12/ET.  In the event that this is not possible due to unforeseen circumstances, a different 
evaluator may evaluate the subject. Al l evaluator s must pass the study training including lesion 
count training. It is particularly important to ensure the same evaluator performs the Baseline and Week 12/ET for lesion counts for a subject , 
7.1.2 Other Assessments  
[IP_ADDRESS] BOTE Inflammation Score  
Inflammator y reactions around MC lesions has been associated with imminent resolution of MC 
(sometimes referred to as “beginning-of-the-end” [“BOTE”] signs). Investigators should educate subjects and caregivers on the characteristic stages of BOTE as it is recognized  as the natural 
course of self -limiting clearance of MC. BOTE may be associated with itching, but not pain. 
BOTE is usually asymptomatic, self -limited, localized to individual MC lesions, and does not 
require discontinuation of study treatment or additiona l treatment.  
Investigators will assess the treatment area at each scheduled visit and use their medical judgement to differentiate between BOTE and LSRs. The BOTE Inflammation Score will be recorded at each visit ( Table 5).  
  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 50 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Table 5 BOTE Inflammation Score  
Score  Global Assessment  Description  
0 No inflammation  No evidence of local inflammation 
1 Mild  Minimal erythema and/or edema 
2 Moderate  Definite erythema and/or edema with or without 
hemorrhagic crusting  
3 Severe  Erythema and edema with definite hemorrhagic crusting 
4 Very Severe  Strong reaction spreading beyond the treated area, bullous reaction, erosions 
[IP_ADDRESS] Investigator Global Severity Assessment  
The Investigator Global Severity Assessment will be completed by [CONTACT_34678], Week 12, and Week 24. The investigator will be asked to answer the following question:  
Please choose the response below that best describes the overall molluscum severity of the 
subject . 
0. None 
1. Mild  
2. Moderate  
3. Severe  
4. Very severe  
[IP_ADDRESS] Subject Global Severity Assessment  
The Subject Global Severity Assessment will be completed by [CONTACT_941] s ubject/caregiver to assess 
overall impression of severity of MC and completed at Baseline, Week 12, and Week 24. The subject or caregiver will be asked to answer the following question:  
Please choose the response below that best describes the severity of your/your child’s molluscum 
contagiosum today. 
0. None 
1. Mild  
2. Moderate  
3. Severe  
4. Very severe  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 51 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   [IP_ADDRESS] Investigator Global Impression of Change 
The Investigator Global Impression of Change will be completed by [CONTACT_34679] 12 and 24. 
The investigator will be asked to answer the following question:  
Please choose the response below that best describes the overall change in the subject’s molluscum contagiosum since he or she started taking the study medication. 
1. Very much improved 
2. Much improved 
3. Minimally improved  
4. No change 
5. Minimally worse  
6. Much worse 
7. Very much worse 
[IP_ADDRESS] Subject Global Impression of Change 
The Subject Global Impression of Change will be completed by [CONTACT_423]/caregiver to assess 
their overall impression of change from baseline in overall MC condition at Weeks [ADDRESS_34285] or caregiver will be asked to answer the following question:  
Please choose t he response below that best describes the overall change in your/your child’s  
molluscum contagiosum since you/your child started applying the study medication. 
1. Very much improved 
2. Much improved 
3. Minimally improved  
4. No change 
5. Minimally worse  
6. Much worse 
7. Very much worse 
[IP_ADDRESS] Study Exit Interview 
Study exit interviews may  be conducted with a selected subset of subjects that complete Week 
12. Consent will be obtained starting at Basel ine, and the professional interview will be 
performed with the subject/caregiver  after completion of Week 12. The objective of the 
interview is to better understand the subject/caregiver perspective of their MC and treatment 
experience.  
7.2 Safety  Assessments 
7.2.1 Physical Exam 
A brief p hysical examination will be performed to evaluat e objective anatomic findings. This 
physical examination will be performed at Baseline and at Week 12/ET. At Baseline, the physical examination will include a directed examination of the skin condition prior to any 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 52 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   application of study drug. This skin asses sment will include the presence or absence of 
individual features of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and 
erosion/ulceration. Any clinically significant changes in the physical exam from baseline will be recorded as AEs.  
7.2.[ADDRESS_34286]- menopausal or surgically sterile (see Section  9.4). UPTs will be collected at Screening  (if in 
-clinic visit) , Baseline, and Week 12/ET. In addition to having a negative UPT at Baseline, 
before the first application of study drug, females who are [ADDRESS_34287] be 
willing to use an acceptable form of birth control during the study. The following are considered 
acceptable methods of birth control for this study: hormonal contraceptives (combined estrogen and progestogen or  progestogen only, including oral, injectable, tr ansdermal or injectable 
formulations) ; intrauterine device (IUD) ; intrauterine hormone releasing system (IUS) ; bilateral 
tubal occlusion or ligation if performed ≥  3 months prior to Baseline; same sex partner or partner 
who has had a vasectomy  ≥ 3 months prior to Baseline ; sexual abstinence with a documented 
acceptable method of birth control if the subject becomes sexually active; female o r male 
condoms with or without spermicide ; or a cervical cap, diaphragm, or sponge with spermicide. 
Women with tubal occlusion or ligations  or whose partner had a vasectomy  will be required to 
complete UPTs at the required timepoints  if their procedure was done < [ADDRESS_34288]’s medical history if applicable . 
7.2.3 Local Skin Reaction Assessment  
The investigator (or designated evaluator) will assess localized skin reactions (LSRs) at Baseline (at least [ADDRESS_34289]-dose), and at any time during the visit at Weeks 2 , 4, 8 and 12. The 
individual components of LSRs are scored separately on a scale of 0-4, with higher numbers indicating more severe reactions. The individual components include erythema, flaking/scaling, 
crusting, swelling, vesiculation/pustulation, and erosion/ulceration .  
Compared to BOTE, LSR s are generally more diffuse, associated with significant itch or 
tenderness, may necessitate discontinuation of study treatment,  and may need treatment for 
symptomatic relief (e.g. a topi[INVESTIGATOR_34621]). For very severe LSR, systemic corticosteroids may be considered. 
Investigators will assess the treatment area at each scheduled visit  and use their medical 
judgement to differentiate between BOTE and LSRs. When LSRs are clinically significant  in the 
opi[INVESTIGATOR_871] (i.e. they interfere with the subject’s normal daily activities) , s/he 
should report the condition as an AE(s) (e.g. application sit e erythema, application site edema) . 
Clinically significant LSRs that are reported as adverse events and/or subject reported 
intolerability (i.e. itching, pain) may result in an investigator directed temporary treatment hold 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 53 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   (drug holiday), and topi[INVESTIGATOR_34595] [ADDRESS_34290] may re-initiate study drug treatment prior to the next scheduled visit. Upon re- initiation 
(challenge) of study drug treatment, if a subject develops worsening LSRs (more severe than the 
first LSR s), allergic contact [CONTACT_34647]. In the event of suspected allergic 
contact [CONTACT_8748], photographs may be taken of the affected area(s) and transmitted to the CRO 
medical monitor for review and confirmation of allergic contact [CONTACT_34680]. Consent must be in place for patch testing to occur. The investigator should also discuss the necessity of patch testing with the subject/caregiver. The investigator will then discontinue the subject from study drug treatment and treat the area(s) with corticosteroids for up 
to [ADDRESS_34291] provides consent/assent, the investigator will consult the CRO medical 
monitor to implement the process for patch testing. S ee Section  7.2.5 for information  on patch 
testing.  
Table 6 Local Skin Reaction Scale 
 Erythema  
Flaking/ 
Scaling  Crusting  Swelling  Vesiculation/ 
Pustulation  Erosion/ 
Ulceration  
0 Not present Not present Not present Not present Not present Not present 
1 Slightly pi[INVESTIGATOR_34622], 
limited  Isolated 
crusting Minimal, 
limited  Fine vesicles  Superficial 
erosion 
2 Pi[INVESTIGATOR_34623]       
< 50%  Mild, 
palpable Scant 
transudate or 
exudate Moderate 
erosion 
3 Red, 
restricted to 
treatment area  Coarse  Crusting       
> 50%  Moderate  Moderate 
transudate or 
exudate Marked, 
extensive 
4 Red 
extending 
outside 
treatment area  Scaling 
extending 
outside 
treatment 
area Crusting 
extending 
outside 
treatment 
area Marked 
swelling 
extending 
outside 
treatment 
area Marked 
transudate or 
exudate Black eschar 
or ulceration  
7.2.4 Scarring/Keloid Assessment  
Scar formation (scars/keloids/hypertrophic scars) will be assessed starting at the Week 4 visit 
through Week 12 and again at Week 24 . Using the lesion map as a guide, the investigator will 
assess the treated areas for scar/keloid formation. All scars, including keloid/hypertrophic scars, 
that develop after the Baseline assessment should be captured as AEs and assessed for 
relatedness to study treatment.  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34292] expe riences a stronger LSR  (second LSR 
event ) than the first LSR event, allergic contact [CONTACT_34647]. In order to confirm 
whether the reaction is allergic contact [CONTACT_8748], patch testing should be conducted. If the 
investigator determines that patch testing is appropriate, he/she should contact [CONTACT_34681]. Patch testing supplies will be  provided once requested from the 
CRO medical monitor.  Additional drug product for patch testing may be supplied through IWRS 
if the currently assigned subject’s investigational product was assigned more than 60 days prior 
to the patch testing date(s) or if the subject had previously returned all their drug product. 
Additionally, patch testing should be discussed with the subject/caregiver. If the 
subject/caregiver consents to patch testing and once the LSR has been completely resolved for a period of [ADDRESS_34293] 
dermatitis should be recorded as the reason for discontinuation. Week 12/ET assessments should 
be completed at the time of discontinuatio n.  
In the event of suspected allergic contact [CONTACT_34682], photographs may  be taken of the 
affected area(s) and transmitted to the CRO medical monitor for review prior to initiating patch 
testing. See Appendix [ADDRESS_34294]’s last visit. Treatment -related adverse events  and serious adverse events 
will be followed up until resolution or up to one year after last treatment, whichever occurs earlier.  
If a subject’s treatment is discontinued by [CONTACT_34649], that AE should be indicated as the reason for treatment discontinuation. All subjects will be encouraged to remain in the study and to complete all required study visits throughout the 24-week study duration. 
If a subject achieves complete clearance at Week 12 or before and experiences new lesions 
between Week 12 and Week 24, an AE of molluscum contagiosum should be documented to capture this recurrence since there is no lesion count after Week 12. 
See Section  9 for additional information regarding adverse events. 
8 STUDY DRUG TREATMENT  
8.1 Description of Products  
Study drug treatment will include once daily application of SB 206 10.3% or Vehicle (placebo) 
gel. Each dose will consist of berdazimer gel  or vehicle gel that will need  to be mixed with 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34295] or caregiver to 
the affected designated area(s).  
All study drug treatments will be manufactured and provided by [CONTACT_456]. The  study 
treatments and their attributes are described in Table 7. 
Table 7 Study Drug  
 SB206 10.3%  Vehicle gel  
Study Drug Components  Berdazimer gel 2 2.7% and  buffered 
hydrogel  
Mixed immediately prior to application  Vehicle gel  and buffered hydrogel  
Mixed immediately prior to application  
Name [CONTACT_34703] 3 x 14g aluminum 
tubes of berdazimer gel and 3 x 14g 
aluminum  tubes of hydrogel  One kit will include 3 x 14g a luminum 
tubes of vehicle gel  and 3 x 14g 
aluminum  tubes of hydrogel  
Storage Requirements  Refrigerated, horizontal  
2-8°C until dispensed  Refrigerated, horizontal   
2-8°C until dispensed  
Appearance Post -Mixing  Opaque white gel  Opaque white gel  
Dosing Schedule  QD QD 
Route of Administration  Topi[INVESTIGATOR_34624]. Novan has updated the naming convention to use percent berdazimer. Therefore, SB 206 1 2% 
(nominal berdazimer sodium) is the same admixture formulation as SB 206 10.3% (berdazimer). In this protocol , 
the nominal berdazimer sodium numbers remain in historical studies.  
8.1.[ADDRESS_34296] is comprised of an active gel  component containing the berdazimer sodium drug 
substance, and a buffered hydrogel (aqueous) component that when mixed releases nitric oxide. Berdazimer sodium  is silsesquioxanes, 3- (2-hydroxy-1-methyl-2-nitrosohydrazinyl)propyl 3-
(methylamino)propyl, polymers with silicic acid (H
4SiO 4) tetra -Et ester, hydroxy- terminated, 
sodium salts.  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 56 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Figure 4 Structure of Berdazimer Sodium  (active ingredient in SB 206) 
 
8.[ADDRESS_34297] ’s lesion s have been confirmed by [CONTACT_34683] [ADDRESS_34298] or caregiver following training by [CONTACT_779]. Subsequent applications of study drug occur at home or on-site at the  clinic visits at Week 2, Week 4 (if the visit is perf ormed in clinic), Week 8, and 
Week 12 . Subjects will return  their kit to each clinic visit for weight and retraining purposes ; at 
Week [ADDRESS_34299]’s/caregiver’s role in tre atment of lesions:  
• Continuous daily treatment of treatable lesions to Week 4 at a minimum 
• Continued treatment of treatable lesions  after Week 4  unless otherwise instructed by [CONTACT_3786] 
• Self-initiate d treatment of new or recurrent lesions  
• Documentation of daily dose application in subject diary 

NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 57 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Withdrawal and discontinuation are covered in Section  6.8. 
8.3 Treatment Allocation  
Subjects will be randomly assigned in a 1:1 fashion to either SB206 10.3% or Vehicle  gel.  
8.4 Randomization Strategy and Procedure 
The randomization schedule will be computer generated using a permuted block algorithm and 
will randomly allocate IP to randomization numbers. As subjects qualify to be randomized into 
the study, a randomization number will be assigned through a central IWRS. At randomization, subjects will be stratified by [CONTACT_34641] (dermatologist vs. other), the subject’s BOTE score at Baseline (no i nflammation (BOTE = 0) vs. mild/moderate/severe inflammation (BOTE 
≥ 1) and number of randomized subjects per household ([ADDRESS_34300] per household vs. 2 subjects per household). Subjects will be stratified to [ADDRESS_34301] of the study.  
8.5.1 Unblinding Procedures  
[IP_ADDRESS] Planned Unblinding 
Individual treatment unblinding is discouraged since knowledge of the treatment assignment will 
not materially change the planned management of a medical emergency. Unblinding should be 
discussed in advance with the medical monitor if possible. Study personnel will utilize the IWRS 
for emergency unblinding. If the investigator is not able to discuss treatment unblinding in advance, then he or she must notify the CRO medical monitor as soon as possible about the unblinding incident without revealing the subject’s treatment assignment. The investigator or 
designee must record the date and reason for study discontinuation on the appropriate eCRF for 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34302]’s treatment assignment.  
If treatment assignment is unblinded for an individual subject, study personnel will be notified of 
that subject’s treatment assignment without unblinding the treatment assignments for the remaining subjects in the study. Thus, the overall study blind will not be compromised. If a 
subject’s treatment assignment is unblinded, he or she may or may not be asked to withdraw 
from the study. The investigator will make this decision after consultation with the medical monitor. 
Of note, all available unblinded safety data will be provided to the DSMB to review after 
approximately 200 subjects are randomized . Personnel who are not otherwise involved in the 
study will prepare the unblinded data and summary tables for this analysis. 
 
[IP_ADDRESS] Unplanned or Unintentional Unblinding 
All instances of unplanned or unintentional unblinding will be documented. 
8.[ADDRESS_34303] diary and from additional information noted in the source (e.g. investigator instructed interrupted or modified doses).  
8.7 Prior and Concomitant Therapi[INVESTIGATOR_34625], prior MC  medications /therapi[INVESTIGATOR_34626] 6 months of Screening will be 
recorded.  Subjects receiving medicinal treatment or other therapy for MC  as defined in the study 
Exclusion Criterion #4, 5, or [ADDRESS_34304] received an 
investigational drug/device within 14 days or 5 half-lives (whichever is longer) prior to Baseline 
as described in Exclus ion Criterion #13 may enter a washout period of up to 14 days prior to the 
Baseline visit ( Section  5.2). 
Initiation of new medications and changes to  ongoing medications will be reviewed and 
documented at each study visit from Screening through Week 24, as well as at Unscheduled Visits. Any medication/therapy used by [CONTACT_34684] a concomitant medication (e.g., aspi[INVESTIGATOR_248], acetaminophen, birth control pi[INVESTIGATOR_3353], vitamins, etc.). Every attempt should be made to keep concomitant medication/therapy dosing constant during the study. Any change to concomitant medications/therapi[INVESTIGATOR_34627]’s study record and in the study database. When applicable, an AE should be completed for any subject starting a concomitant medication/therapy after enrollment into the study. 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 59 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Clinically significant LSRs (e.g., those that interfere with a subject’s normal daily activities) that 
are reported as adverse events and/or subject reported intolerability (i.e. itching, pain) may result 
in an investigator directed temporary treatment hold (drug holiday), and topi[INVESTIGATOR_19529] l corticosteroids 
may be used to treat LSRs for up to [ADDRESS_34305] may re- initiate study drug treatment 
prior to the next scheduled visit. Upon re-initiation (challenge) of study drug treatment, if a 
subject develops worsening LSRs, allergic contact [CONTACT_34647]. In the event of 
suspected allergic contact [CONTACT_8748], the investigator will discontinue the subject from study drug treatment and treat the area(s) with corticosteroids for up to [ADDRESS_34306] provides consent/assent, the investigator will consult the CRO medical monitor to implement the process 
for patch testing 
8.7.1 Prohibited Therapi[INVESTIGATOR_34628]. Use of topi[INVESTIGATOR_34629] 2 cm of MC lesions is prohibited within 14 days of baseline and during the study. Use of the following concomitant medications to treat MC 14 days prior to 
baseline and during the study is prohibited: podophyllotoxin, imiquimod, cantharidin, 
sinecatechins, topi[INVESTIGATOR_34630], oral or topi[INVESTIGATOR_34611], other homeopathic or over-the-counter 
products including, but not limited to, ZymaDerm and tea tree oil, cimetidine and other histamine H2 receptor antagonists. S urgical procedures to treat MC ( e.g. cryotherapy, curettage) 
are prohibited during the study. The CRO medical monitor should be contact[CONTACT_34685][INVESTIGATOR_014]. 
[ADDRESS_34307]’s last visit. In order to avoid bias in eliciting AEs, subjects/caregivers 
should be asked the following non-leading question: “How have you felt since your last visit?” 
SAEs will be collected from the time of consent through the end of the subject’s last visit. Adverse events that occur from time of consent up to the time of treatment administration should be recorded as medical history for all participants. Serious adverse events will be followed until 
resolution. 
9.1 Definitions  
• Adverse event – An AE is any untoward medical occurrence associated with the use of an 
intervention in humans whether or not it is considered intervention- related.  
• Serious adverse event (SAE) – An event is considered “serious” if, in the view of either 
the investigator or sponsor, it results in any of the following outcomes:  
− Death  
− A life -threatening AE (An event is considered “life -threatening” if, in the view of 
either the investigator or s ponsor, its occurrence places the patient or subject at 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 60 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   immediate risk of death. It does not include an AE or suspected adverse reaction (AR) 
that, had it occurred in a more severe form, might have caused death.) 
− Inpatient hospi[INVESTIGATOR_1081] 
− A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
− A congenital anomaly/birth defect 
− Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical  intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
• Causality or relatedness – Determination of whether there is a reasonable possibility that 
the product is causally related to the adverse event. Causality assessment includes, for example, evaluation of temporal relationships, dechallenge/rechallenge information, association with (or lack of association with) underlying disease, presence (or absence) of 
a more likely cause, and biologic plausibility.  
• Adverse reaction – An AR is any AE caused by a drug. 
• Suspected adverse reaction (SAR) – An SAR is any AE for which there is a reasonable 
possibility that the drug caused the AE. For the purposes of IND safety reporting, “reasonable possibility” means there is evidence to suggest a causal relationship between the drug and the AE. SAR implies a lesser degree of certainty about causality than AR. 
• Unexpected – An event is considered unexpected if it is not listed in the IB, is not listed at the specificity or severity that has been observed, or, if an IB is not required or available, is not consistent with the risk information described in the General Investigational Plan or elsewhere in the IND. Unexpected also refers to events that are 
mentioned in the IB as occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug but are not specifically mentioned as occurring with the particular drug under inves tigation.  
9.2 Documenting Adverse Events  
All AEs (serious and non-serious) reported by [CONTACT_34686]’s 
study record and entered into the study database no later than 5 days of the site’s first knowledge. 
The site must report all SAEs to the CRO within [ADDRESS_34308] knowledge of the event by [CONTACT_3452]. The date of onset, date ended, accurate event term, seriousness, severity, outcome, causality ( relationship to study drug), therapy required, and action taken regarding study drug 
and study participation will be reported for each AE. 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 61 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   Significant LSRs (as judged by [CONTACT_093]), scarring , and hypertrophic/keloid scars will be 
captured as adverse events.  
9.2.1 Assessment of Severity  
The investigator is responsible for evaluating all AEs and determining the severity of the event.  
Severity will be categorized according to the following definitions: 
• Mild:  Event may be noticeable to subject; does not influence daily activities; usually does not require intervention 
• Moderate: Even t may be of sufficient severity to make subject uncomfortable; 
performance of daily activities may be influenced; intervention may be needed 
• Severe:  Event may cause severe discomfort; usually interferes with daily activities; 
subject may not be able to continue in the study; treatment or other intervention usually 
needed  
9.2.2 Assessment of Causality  
Several factors should be considered when assessing the relationship (causality) of an event to the study drug or administration of the study drug. T he investigator should assess the relatedness 
to the study drug using a standard of a reasonable possibility of a causal relationship between the study drug and the AE, as per the examples in Table 8: 
Table 8 Assessment of Causality  
Related Events :  
Include those assessed 
as definitely, possibly, 
or probably related 
events  • Reasonable temporal sequence to drug administration  
• Event can be fully attributable to administration of the study drug  
• Known pharmacological action of the study drug  
• Specific tests available (positive allergy test, antibodies, metabolites)  
• As adverse drug reaction in the product information (Investigator’s Brochure ) 
• Reported in the literature as a possible side effect  
• Dechallenge (event abates on discontinuation of the study drug/without treatment)  
• Rechallenge positive (event reappears on re -exposure to study drug)  
• Not explained otherwise by [CONTACT_423]’s clinical state or medical history or by [CONTACT_34687]/therapi[INVESTIGATOR_014], etc.  
Unrelated Events :  
Include those assessed 
as unlikely or 
unrelated  events  • No reasonable temporal sequence to study drug administration  
• Event is explained by a number of other factors such as a subject’s clinical state, 
medical history,  or other concomitant agents/therapi[INVESTIGATOR_014]  
• Etiology has been clarified and is in no way related to the study drug  
• No reason for suspecting a causal relationship to the study drug and  
• Investigators have established this beyond reasonable doubt  
 
9.2.[ADDRESS_34309] be reported to the CRO as soon as possible 
after the investigator  or coordinator has become aware of its occurrence. The investigator/ 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34310]:  
1. Report the SAE or pregnancy immediately  (within 24 hours) after the investigator becomes 
aware of the event.  
2. Complete an SAE or pregnancy notification f orm and send the appropriate reporting form to 
the C RO within [ADDRESS_34311]’s treatment and follow-up and document as 
appropriate. 
4. Provide a more detailed r eport to both the CRO  and the IRB, if applicable, no later than 
seven days after the investigator discovers the event as further information becomes 
available, and when necessary update the information with follow-up information including 
outcomes. This report should include a statement as to whether the event was or was not 
related to the use of study drug. 
5. The investigator will notify the IRB of the SAE or pregnancy according to specific IRB requirements.  
6. The investigator will collect information on SAEs until the subject’s health has returned to baseline status, until all parameters have returned to normal, or remaining health issues have otherwise been explained. 
7. The investigator is responsible for following pregnancies through the end of the pregnancy and for providing the assessment of the healthy live birth or for reporting any abnormal 
pregnancy outcome such as stillbirth, miscarriage, or deformity to the CRO/sponsor. 
For clarity on how to record an adverse event that progresses into a serious adverse event, there 
should be two events recorded: the first event would be the beginning adverse event, and the second event would be the serious adverse event (i.e. only the time the AE qualified as serious). 
Resolution of the SAE should be recorded in the same manner, two end dates for SAE and AE, 
where the SAE and AE may or may not share the same end date.  
9.[ADDRESS_34312] scheduled study visit (Week 24/ET2) must be 
recorded in the study database as ongoing/not recovered/not resolved/resolving. Treatment 
related adverse events  and serious adverse events , including LSRs and scars/keloid s, will be 
followed until resolution or up to [ADDRESS_34313] completes 
study participation at Week 24/ET2. Resolution means the subject has returned to the baseline 
state of health, or the investigator does not expect any further improvement or worsening of the subject’s condition. 
9.4 Women of Child bearing Potential & Pregnancy  
A female is considered of childbearing potential if she has reached [ADDRESS_34314]-menopausal (no menses for 12 consecutive months), surgically sterilized (documented 
hysterectomy, documented bilateral salpi[INVESTIGATOR_1656], documented bilateral oophorectomy). Tubal ligation does not meet the definition of surgically sterile.  
WOCBP must use an effective method of birth control during the study. The following are 
considered acceptable methods of birth control for this study: hormonal contraceptives 
(combined estrogen and progestogen or progestogen only, including oral, injectable, transder mal 
or injectable formulations); intrauterine device (IUD); intrauterine hormone releasing system (IUS); bilateral tubal occlusion or ligation if performed ≥ 3 months prior to Baseline; same sex 
partner or partner who has had a vasectomy; sexual abstinence .with a documented acceptable 
method of birth control if the subject becomes sexually active; female or male condoms with or without spermicide; or a cervical cap, diaphragm, or sponge with spermicide. Women with tubal occlusion or ligations  or whose part ner has had a vasectomy  will be required to complete UPTs 
at the required timepoints  if the procedure was done < [ADDRESS_34315] review guidelines about study participation including the topi[INVESTIGATOR_34631]: 
• Informed consent document 
• Pregnancy prevention information 
• Risks to unborn child(ren) 
• Any drug interactions with hormonal contraceptives 
• Contraceptives in current use 
• Guidelines for the follow-up of a reported pregnancy  
Prior to study enrollment, all subjects must be advised of the importance of avoiding pregnancy during participation in this clinical study and the potential risk factors for an unintentional pregnancy. The subject must sign an informed consent document stating that the above-mentioned risk factors and the consequences were discussed.  
During the study, females who have reached the age of menarche should be instructed to contact [CONTACT_28265] (e.g., missed or late 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 64 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   menstrual cycle). Study drug shall be held immediately if a subject is suspected to be pregnant 
and study drug must be permanently discontinued if pregnancy is confirmed. The investigator 
must immediately notify the medical monitor/CRO of a ny female subject who becomes pregnant 
any time during study participation, record the information on the pregnancy notification form and email the form to the CRO. Subjects found to be pregnant prior to Week [ADDRESS_34316] periodically during the pregnancy for ongoing health and safety information through the end of the pregnancy, as applicable. The investigator is responsible for following the pregnancy through the end of the 
pregnancy and for providing the assessment of the healthy live birth or for reporting any 
abnormal outcome such as stillbirth, miscarriage, or deformity to the CRO/sponsor (Not e: 
Congenital anomal ies  are considered SAEs and require separate reporting per Secti on 9.2.3). 
9.[ADDRESS_34317] supportive care should 
be utilized. Methylene blue may be used to treat subjec ts exhibiting methemoglobinemia . The 
medical monitor/CRO/sponsor must be notified of any subject exhibiting signs of 
methemoglobinemia.  
10 ANALYSIS 
10.1 Hypothesis 
This study is intended to formally evaluate the efficacy of SB206 10.3% QD against Vehicle.  
The primary efficacy comparison will test the following hypotheses: 
H0: The proportion of subjects with complete clearance is equal between SB206 10.3% 
QD and Vehicle;  
H1: The proportion of subjects with complete clearance is different between SB206 10.3% QD and Vehicle.  
10.2 Population 
10.2.1 Sample Size Rationale 
Approximately 850 subjects, 6 months of age and older, with a minimum of 3 and a maximum of 
70 MC lesions at Baseline will be randomized in a 1:1 (active:vehicle) scheme. The sample size 
assumptions for this study were informed by [CONTACT_34688] 3 studies NI-MC301 and NI -MC302. Multiple replications of simulated random sampling of the integrated 
NI-MC301 and NI-MC302 data was performed to ensure the sample size assumptions align with 
the proposed design of NI-MC304. This includes the 1:1 ratio (active:vehicle) and the percentages observed in NI-MC301 and NI- MC302 for each stratum of each of the stratification 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 65 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   factors: investigator type, number of randomized subjects per household, and baseline BOTE 
score that are planned for NI -MC304. 
The analysis of the proportion of subjects with complete response of all treatable MC at Week 12 
within the Intent- to-Treat (ITT) Population of the multiple replications of simulated random 
sampled integrated data yields rates of 20% for vehicle and 29.5%  for SB206 10.3% QD with the 
covariate -adjusted treatment difference was 9.5%. A sample size of 850 subjects (425 subjects in 
the SB206 10.3% QD group and 425 subjects in the vehicle group) will provide 90% power for a 2-sided alpha test of size 0.[ADDRESS_34318] an absolute difference of 9.5% when the vehicle response 
rate is 20%.    
10.2.2 Analysis Subsets 
The Intent- to-Treat (ITT) analysis population will include a ll randomized  subjects  who have a 
signed informed consent or assent as applicable. The ITT analysis population will be used as the 
main analysis population for efficacy (primary and secondary) and exploratory endpoints. 
Subjects will be analyzed according to the treatment group to which they were randomized. 
The Per Protocol (PP) analysis population will include all ITT subjects with no significant 
protocol deviations potentially having an impact on the efficacy evaluations. Subjects will be 
analyzed according to the treatment group to which they were randomized. The PP analysis population will be used as a supportive analysis population for the primary and secondary 
efficacy endpoints. 
The Safety analysis population will include all ITT subjects who r eceived at least one dose of the 
study treatment. Subjects will be analyzed according to the study treatment actually received. 
The Safety analysis set will be used for the summary of demographic and other baseline characteristics, prior and concomitant medications, exposure and compliance with the study 
drug, and all safety endpoints.  
10.2.3 General Considerations  
Continuous variables will be summarized by [CONTACT_6982], when applicable, using 
the number of subjects with non-missing data (n), mean, standard deviation (SD), median, minimum,  and maximum. Categoric al variable s will be summarized by [CONTACT_29013], when applicable, using frequencies and percentages. 
All statistical tests will be two -sided and will be performed with a significance level of 0.05, 
unless otherwise specified. Additional details regarding the analysis of primary, secondary, exploratory , safety endpoints 
and all sensitivity analysis will be included in the SAP. The SAP will be finalized before 
unblinding and database lock. 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 66 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   10.3 Testing Procedures  
10.3.1 Analysis of the Primary Efficacy Endpoint  
The primary efficacy endpoint for this study is the proportion of subjects achieving complete 
clearance of all treatable molluscum lesions  at Week 12 for the ITT population. Complete 
clearance of all MC at Week 12 is defined as having a lesion count of 0 at Week 12. The number 
and percentage of subjects with complete clearance at Week 12 will be summarized by [CONTACT_1570].  
The primary ef ficacy endpoint will be analyzed using a generalized estimating equation (GEE) 
for logistic regression with an exchangeable working correlation structure. The model will 
include treatment, investigator type (dermatologist vs other), B aseline BOTE score (no  
inflammation (BOTE = 0) vs. mild/moderate/severe inflammation (BOTE ≥ 1) and number of 
randomized subjects per household ([ADDRESS_34319] per household vs. 2 subjects per household), age 
and Baseline lesion count as factors. The odds ratio between SB206 10.3% a nd vehicle gel, 95% 
CIs for the odds ratio, and P- value for the covariate- adjusted treatment comparison will be 
presented ; together with predicted proportions along with their associated 95% confidence 
interval. Only subjects who achieve complete clearance at Week [ADDRESS_34320] to the primary endpoint and secondary endpoints will be 
strongly controlled at the alpha=0.05 level using a hierarchical fixed sequence method testing 
strategy. If the primary endpoint is not statistically significant at the alpha=0.05 level, the secondary efficacy endpoints will be considered not significant. If the primary endpoint is statistically significant at the alpha=0.05 level, the secondary efficacy endpoints will be tested in 
the following hierarchical fixed sequence: 
• Proportion of subjects achieving a lesion count of 0 or 1 of all treatable MC at Week 12 
• Proportion of subjects achieving at least a 90% reduction from Baseline in the number of 
all treatable MC at Week 12  
• Proportion of subjects with complete clearance of all treatable MC at Week 8  
• Percent change from Baseline in the number of all treatable MC  at Week [ADDRESS_34321] of the secondary efficacy endpoint s, if the secondary endpoint is not 
statistically significant at the alpha=0.05 level, the remaining secondary efficacy endpoints will 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 67 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   be considered not significant. If the secondary endp oint is statistically significant at the 
alpha=0.05 level, the next subsequent secondary efficacy endpoint will be tested following the 
sequence.  
10.3.3 Population Analysis 
[IP_ADDRESS] Disposition  
Subject disposition information will be summarized for all subjects by [CONTACT_34689]. 
Summaries will include: the number of subjects screened, the number of subjects in each 
analysis population, the number of subjects where study treatment stopped, primary reason for 
study treatment stopped, the number of subjects completing 12 weeks of the study, the number of subjects completed the study, and the primary reason for discontinuation. 
[IP_ADDRESS] Demographics and Baseline Characteristics  
Demographic variables include age, sex, ethnicity, and race. Age will be calculated in years 
relative to the  informed consent date.  
Other baseline characteristics include lesion counts at baseline, baseline BOTE score, site type 
(dermatologist vs other) , and age at and time since onset of symptoms of current molluscum 
epi[INVESTIGATOR_1865]. Demographic and baseline character istics will be summarized for the Safety, ITT, and 
PP Populations. 
10.3.4 Safety Analysis 
No missing safety data will be imputed, and no inferential statistics will be done for any safety 
endpoints. Change from Baseline in abbreviated physical examinations and a summary of concomitant medications will be presented.  
[IP_ADDRESS] Adverse Events  
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA 
Version 23.0 or later ). 
A treatment -emergent AE (TEAE) is defi ned as those AEs that occurred any time on or after the 
first in -clinical application of study drug through the last application of study drug and those 
existing AEs that worsened during this same period. If it cannot be determined whether the AE is 
treatment emergent due to a partial onset date, then it will be counted as such. 
TEAEs will be summarized by [CONTACT_1196] (SOC) and Preferred Term (PT). For the 
summary by [CONTACT_3592], each subject will be counted only once within a SOC or a PT. AEs 
with an  outcome of death, SAEs, TEAEs leading to discontinuation from study treatment, and 
TEAEs leading to discontinuation from the study will be summarized similarly.  
TEAEs will be further summarized by [CONTACT_34690], separately. For the summary by [CONTACT_34691], each subject will be counted only once 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34322] reported relationship with study treatment. 
Separate listings will be provided for the AEs with an outcome of death, SAEs, TEAEs leading 
to discontinuation from study treatment, and TEAEs leading to discontinuation from study. 
The proportion of subjects with scarring and the proportion of subjects with keloid or 
hypertrophic scarring will be summarized descriptively. 
[IP_ADDRESS] Local Skin Reaction s 
The LSR composite score will be calculated by [CONTACT_34692] (0-4) to 
each individual parameter for a composite score that ranges between 0 and 24. The change from 
Baseline of the LSR composite score will be summarized descriptively. A table summariz ing 
each LSR parameter (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and 
erosion/ulceration) score at each scheduled postbaseline assessment will be presented. Additionally, a shift table comparing the baseline score for each LSR parameter to each 
scheduled postbaseline assessment will be presented for the Safety Population. 
10.3.[ADDRESS_34323] -baseline assessment 
will be presented for the Safety Population. Additi onal BOTE vs lesion count/complete clearance 
analyses may be explored and further detailed in the SAP. 
10.3.6 Exploratory Analysis 
The exploratory endpoints based on the proportion of subjects achieving complete clearance (at 
Weeks 2, 4) or 75%  (at Weeks 2, 4, 8, 12) , 90%  (at Weeks 2, 4, 8) reductions will be analyzed in 
the same manner as the primary endpoint.  
Likewise, the p roportion of subjects achieving a lesion count of [ADDRESS_34324] be conducted in compliance with the protocol, the ICH Guidance for Industry E6 (R2) Good Clinical Practice: Consolidated Guidance and the applicable regulatory 
requirements. T he investigator must submit all essential regulatory documentation, as required 
by [CONTACT_27952] (including approval of the protocol and informed consent/assent form by [CONTACT_2717]) to the CRO before investigational product will be shipped to the study site. The investigator will review the final study results to confirm that to the best of his /her knowledge, it 
accurately describes the con duct and results of the study. 
11.[ADDRESS_34325] (DSMB) 
When approximately [ADDRESS_34326] (DSMB) 
will review all available unblinded safety data (including completed patch testing results). The DSMB will provide their recommendation for the study to proceed or not proceed. 
11.3 Ethics Review  
The protocol, informed consent/ assent form(s), recruitment materials, and all participant 
materials will be submitted to the Institutional Review Board (IRB) for review and approval. 
Approval of both the protocol and the consent/assent form must be obtained before any subject is screened. Any amendment to the protocol will require review and approval by [CONTACT_3484]. In addition, all changes to the consent/assent form will be 
IRB-approved; a determination will be made regarding whether a new consent needs to be 
obtained from subjects who provided consent using a previously approved consent form. 
11.4 Informed Consent  
In compliance with 21 C.F.R. § 50.25, informed consent is a process that is initiated prior to the 
subject agreeing to participate in the study and continues throughout the subject’s study 
participation. This study may include both paper-based informed consent/assent forms, and 
electronic consent/assent forms. All c onsent/assent forms will be IRB-approved and the subject 
will be asked to read and review the document. The investigator will explain the research study to the subject and answer any questions that may arise. A verbal explanation will be provided in 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34327]’s comprehension of the purposes, procedures, and potential risks of 
the study, alternative treatment options,  and of their rights as research subjects. Subjects will 
have the opportunity to carefully review the written consent/assent form and ask questions prior 
to signing. The subjects should have the opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to participate. The informed consent/assent 
document should be signed prior to any procedures being done specifically for the study. 
Subjects must be informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the informed consent/assent document will be given to the subjects for their records. The informed consent process will be conducted and 
documented in the source document (including the date), and the form signed, before the subject 
undergoes any study-specific procedures. The right s and welfare of the subjects will be protected 
by [CONTACT_34693].  
11.[ADDRESS_34328] not be disclosed to any person or entity not directly involved with the study unless prior documented  consent is gained from 
Novan. However , authorized regulatory officials, IRB/IEC personnel, Novan  and its authorized 
representatives are allowed full access to the records.  
Subjects will only be identified at a minimum by [CONTACT_34694] . If 
required, the subject's  full name [CONTACT_34704].  
11.6 Disclosure 
The study will be posted to clinicaltrials.gov. 
Novan is responsible for preparing and providing the appropriate regulatory authorities with 
clinical s tudy reports according to the applicable regulatory requirements. 
The publication policy of Novan is discussed in the investigator 's Clinical Research Agreement.  
[ADDRESS_34329] 
Operating Procedures (SOPs) for compliance with applicable government regulations, (i.e., informed consent regulations, (21 CFR § 50.20, 1999), and Institutional Review Board regulations, (21 CFR § 56.103, 1981)). Access to all records, both during the trial and after trial 
completion, should be made available to the CRO and Novan at any time for review and audit to 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34330] the protocol in accordance with applicable GCP regulations and 
guidelines, applicable informed consent regulations (21 CFR § 50.20, 1999), and in compliance with the principles in the Declaration of Helsinki. Every attempt must be made to follow the 
protocol and to obtain and record all data requested for each subject at the specified times. If data 
is not recorded per protocol, the reason(s) must be clearly documented on the study records.  
Before study initiation, at a site initiation visit or at a meeting with the investigator(s), a CRO or 
Novan representative will review the protocol and study records with the investigator(s) and the ir 
staff. During the study, the study monitor will be in regular contact [CONTACT_34695]- site visits in accordance with the monitoring plan. The objective of these 
communications is to review  the completeness of subject records, the accuracy of entries into the 
study database, the adherence to the protocol and to GCP, the progress of enrollment, to ensure 
that consent is being sought and obtained in compliance with applicable regulations, and that the 
investigational product is being stored, dispensed and accounted for according to specifications. The investigator and key trial personnel must be available to assist the monitor during these visits.  
The investigator must give the monitor access to relevant hospi[INVESTIGATOR_34632]. No information in these records about the identity of the subjects will leave the study site . Monitoring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of AEs/SAEs and the recording of primary efficacy and safety variables. Additional checks of the 
consistency of the study records with the study database will be performed according to the study 
specific monitoring plan. 
The investigator or designee must promptly enter the data into the study database after the 
subject’s visit. The monitor is responsible for reviewing them and clarifying and resolving any 
data queries. A copy of the study records will be retained by [CONTACT_34696] a secure place with other study documents, such as the protocol, the Investigator’s Brochure , and any protocol amendments. 
The investigator must provide the responsible IRB with a study summary shortly after study 
completion , as per IRB requirements . 
This study may  incorporate the use of remote monitoring and on- site monitoring visits  based on 
many factors . Risk based monitoring may also be utilized to focus on oversight of subject safety 
and data integrity. Additional details regarding these visits can be found in the clinical monitoring plan.  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34331] an inspection (during the study or even after its completion). If a regulatory authority requests an inspection, the investigator must inform the CRO immediately that this request has been made.  
Study conduct may be assessed during the course of the study by a Quality Assurance representative(s) to ensure that the study is conducted in compliance with the protocol and GCP. 
He/she will be permitted to inspect the study documents (study protocol, study records, study drug, original, study- relevant medical records). All subject data will be treated confidentially.  
12.1.3 Protocol Modification/Deviations 
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be made only by [CONTACT_456]. All protocol modifications should be submitted to the IRB in the form of an amendment, with approval obtained prior to implementation of changes unless the amendment is intended to reduce immediate subject risk.  When the protocol modification 
substantially changes the protocol design or updates the potential study risks section of the Informed Consent Form, the Informed Consent Form will be amended/approved by [CONTACT_1201], requiring all subjects already enrolled to provide informed consent, again. 
This study will be conducted as described in this protocol, except for in emergency situations in 
which the protection, safety, and well-being of the subject requires immediate intervention, 
based on the judgment of the investigator (or a responsible, appropriately trained professional designated by [CONTACT_093]). In the event of a significant deviation from the protocol due to an emergency, accident, or mistake, the investigator or designee must contact [CONTACT_34697]. This will allow an early joint decision regarding the subject’s continuation 
in the study. All deviations, as well as subject participations decisions, will be documented by 
[CONTACT_34698].  
If additional contingency measures that require deviation from the protocol a re enacted, efforts 
will be made to minimize impacts on trial integr ity, and to document the reasons for protocol 
deviations as outlined in the clinical  trial continuity plan.  
12.1.4 Records  
[IP_ADDRESS] Data Capture and Management  
Subject data will be entered into a sponsor- approved electronic database compliant with 21 CRF 
Part 11, into electronic case report forms (eCRFs) and combined with data provided from other 
sources (e.g., laboratory) in validated datasets then transmitted electronically to the sponsor or 
designee.  Management of clinical data will be performed in accordance with the applicable 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 73 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   sponsor-approved standards and data cleaning processes to ensure the integrity of the data. A 
data management plan for the study will be maintained by [CONTACT_2024]. 
Adverse events and prior/concomitant medications and medical history terms will be coded using 
the most current versions of MedDRA and the World Health Drug Dictionary (WHODrug), respectively.  
The investigator will retain original source documents and the sponsor wil l receive eCRF -
required data as electronic datasets.  Subject initials will not be collected or transmitted to the 
sponsor. 
[IP_ADDRESS] Source Documentation 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site investigator. The investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Data recor ded on the eCRF derived from source documents should be 
consistent with the data recorded on the source documents. 
Clinical data will be entered into a [ADDRESS_34332] protection and internal quality checks, such as 
automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. 
Clinical data will be entered directly from the source documents.  
[IP_ADDRESS] Study Files and Records Retention 
It is a Novan requ irement that all investigators participating in clinical studies maintain detailed 
clinical data for one of the following periods, whichever is longest: 
• Country- specific requirements; or  
• A period of at least two years following the last approval of a marke ting application 
approved by a Regulatory Authority in an ICH region or until there are no pending or 
contemplated marketing applications in an ICH region; or, 
• A period of two years after Novan notifies the investigator that the data will not be 
submitted for review by [CONTACT_34699]. 
The investigator must not dispose of any records or essential documents relevant to this study 
without either (1) written permission from Novan, or (2) providing an opportunity for Novan to 
collect such records. The investigator shall take responsibility for maintaining adequate and 
accurate electronic or hard copy source documents of all observations and data generated during this study. Such documentation is subject to inspection by [CONTACT_34700]. If the investigator withdraws from the study (e.g., relocation, retirement), all study-
related records should be transferred to a mutually agreed-upon designee. Notice of such transfer 
will be provided to Novan in writing. 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page 74 of 77  
Novan, Inc.  
Version 3.0, dated 30 Sep 2020   12.2 Study Termination or Study Site Closure  
Both Novan and the principal investigator [INVESTIGATOR_34615]’s site at any time. Should this be necessary, Novan or a specified designee will 
inform the appropriate regulatory authorities of the termination of the study and the reasons for its termination, and the principal investigator [INVESTIGATOR_34616]/IEC of the same. In terminating the study, Novan and the principal investigator [INVESTIGATOR_34617]’ interests. 
13 PUBLICATION POLICY  
Novan is responsible for preparing and providing the appropriate regulatory authorities with 
clinical study reports according to the applicable regulatory requirements. 
Novan’s publication policy is discussed in the investigator's Clinical Study Agreement.  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34333];13(10):877-88. 
Dohil et al., 2006 
Dohil MA, Lin P, Lee J, et al. The epi[INVESTIGATOR_34633]. J Am Acad Dermatol. 2006 Jan;54(1):47-54. 
 
FDA, [ADDRESS_34334] of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards. [ADDRESS_34335] on quality of life of molluscum contagiosum in children in the [LOCATION_006]: a prospective community cohort study. Lan cet Infect Dis. 2015;15(2):190-5/ 
Olsen et al., 2014 
Olsen J, Gallacher J, Pi[INVESTIGATOR_34634] V, et al.  Epi[INVESTIGATOR_34633]: a systematic review.  Fam Pract. 2014 Apr;31(2):130-6. 
Osio et al., 2011 
Osio A, Deslandes E, Saada V, Morel P, Guibal F. Clinical characteristics of molluscum contagiosum in children in a private dermatology practice in the greater Paris area, [LOCATION_009]: a prospective study in 661 patients. Dermatology. 2011;222:314–20. 
Schofield et al., [ADDRESS_34336] new reason people present to general practitioners in England and Wales. Br J Dermatol. 2011;165:1044–50. 
 
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34337] experiences a stronger LSR  (second LSR 
event)  than the first LSR event, allergic contact [CONTACT_34647]. In order to confirm 
whether the reaction is allergic contact [CONTACT_8748], patch testing should be conducted. If the 
investigator determines that patch testing is appropriate  and the patient/caregiver consent to 
patch testing , he/she should contact [CONTACT_34701]. Once the LSR has been 
completely resolved for a period of [ADDRESS_34338]’s investigational product was assigned more than 60 days prior to 
the patch testing date(s) or if the subject had previously returned all their drug product. 
For patch testing: 
• Discontinue study treatment (see Section  7.2.3 regarding LSRs) 
• Document the event as an AE and consult with the CRO m edical monitor. Detailed 
instructions for the patch testing will be provided after discussion with t he m edical 
monitor. 
• When applicable, challenge patch testing should be performed after all signs and 
symptoms of the LSR have been resolved for approximately 2 weeks to 2 months. 
• The randomized study treatment will be applied to a naïve area on the partici pant’s back  
or arm. Use the subject’s most recently assigned study drug kit to obtain material for 
testing.  
• The participant will return to the site approximately 48 hours after the application of the 
patches. Approximately 30 minutes, 24 hours and 48 hours after patch removal, the patch  
site(s) will be evaluated using the scale in  Table 9
. If the 48-hour reading is equivocal, it 
is recommended to evaluate the site at 72 to 96 hours after removal. Take photographs at  
every time point and transmit them to the  medical monitor. Further instructions will be 
given after review of the photos. 
• At the last reading, the invest igator will make the final interpretation of any challenge  
reactions. This last reading (at least 48 hours after patch removal) is critically important 
to distinguish irritant reactions (which fade) from true allergic reactions (which persist) and to ident ify allergic  reactions that do not appear at the time of patch removal. See 
Table 10.  
NI-MC304 Clinical Study Protocol Confidential 
SB206 Page [ADDRESS_34339] Reactions (at each time 
point)  
Score Description  
+/- Doubtful reaction, faint macular erythema  
+ Weak, non- vesicular reaction with erythema, infiltration, and papules  
++ Strong vesicular reaction with erythema, infiltration, and papules  
+++ Spreading bullous reaction  
- Negative reaction  
IR Irritant reaction  
 
Table 10 Challenge Reaction Interpretation  (based on the last  
reading  (at least 48 hours after patch removal) 
Score Description  
Negative  Might include an irrita tive reaction  
Equivocal  Unable to determine  
Positive * Reaction definitely due to sensitization  
 
*Judgement of “positive” reaction should be accompanied by ++ or greater reading at the last reading . 